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ABSTRACT 
Tammy W. Shen: Development and Characterization of PRINT
®
 Particles as Drug Delivery 
Vehicles in the Lung 
(Under the direction of Joseph M. DeSimone) 
 
The aim of this dissertation is to develop and investigate the utility of the Particle 
Replication in Non-wetting Templates (PRINT
®
) technology as a toolbox to generate 
precisely defined particles in shape, matrix, and surface functionality to further the 
understanding of particulate drug delivery to the lung.  The pulmonary route of 
administration is of particular interest in analyzing the effects of particles due to the vast 
exposure of our lungs to a wide array of airborne particulates.  From pollen to bacteria to 
diesel exhaust, the fate and physiological impacts of these particulates cause a multitude of 
disease states in the human body.  Understanding, and even harnessing, the specific 
characteristics which make these airborne invaders so potent at evading or wreaking havoc 
on the body’s defense systems will hopefully lead to the development of more safe and 
efficient drug delivery vehicles. 
Particles of varying geometries were fabricated and shape effects on macrophage 
internalization in vitro were investigated to explore physical particle characteristics that may 
impart the ability to tailor alveolar macrophage uptake for use in pulmonary therapeutics.  
PEG particles ranging from 80x320 nm to 6 µm in diameter were instilled into the lungs of 
mice and cellular uptake, residence time, and inflammatory responses in the lung were 
analyzed. Being able to precisely tune individual particle parameters allowed for the 
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determination of specific characteristics that could target or de-target specific cell 
populations in the lung.  These PRINT particles were also shown to reside in the lung out to 
twenty-eight days without inducing an inflammatory response which demonstrates the 
potential of these particles as immunologically inert drug carriers to the lung.
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CHAPTER 1 
 
INTRODUCTION 
 
The pulmonary route is an attractive option for therapeutic delivery due to its ease of 
access, non-invasive nature, large absorptive surface area, rapid onset of therapeutic action, 
localized drug delivery, and clinical relevance to diseases of the lung.  It is preferred over 
oral drug delivery for many disease states due to its decreased susceptibility to first pass 
metabolism, faster onset of action, higher localized drug concentration, and decreased 
systemic toxicities [1].  Pulmonary drug delivery also has advantages over intravenous drug 
delivery in avoiding invasive dosing methods, such as needles, and, similar to the benefits 
over oral delivery, decreased systemic toxicities and increased local lung concentrations of 
the therapeutic [2].   
The study of particles in the lung spans several different fields of research.  Research 
in environmental health science studies the effects of environmental particulates, such as 
diesel exhaust particles and TiO2 particles, on lung injury, inflammatory responses and 
cellular clearance mechanisms in the lung [3-8].  In pharmaceutical particle engineering, the 
technology of formulating and characterizing aerodynamically relevant particles for drug 
delivery to the lung is an area of high interest in both administration (i.e. dry powder inhalers 
and nebulizers) and therapeutic efficacy [9-11].  In medicine and physiology, the 
pharmacodynamics and pharmacokinetic effects of the drug molecule itself as well as how 
the disease states affect particle deposition and drug release are investigated [1, 12]. 
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Combining the methodology and knowledge from these various particle research areas will 
allow for a more integrated approach to exploring the specific design parameters important 
for drug carriers to the lung. 
 
1.1 Diseases of the Lung 
According to the World Health Organization (WHO), of the top ten leading causes of 
death in the world in 2012, three of the top five were related to diseases of the lung: #3 
chronic obstructive pulmonary disease (COPD), #4 lower respiratory infections and #5 lung 
cancer.  COPD killed 3.1 million people worldwide with smoking as a primary cause of the 
disease.  Smoking was also implicated in 80-90% of patients with lung cancer and led to 1.6 
million deaths in 2012.  It is projected that there will be 1.6 billion smokers worldwide by 
2025 and thus the projected deaths for COPD and lung cancer are expected to increase 
significantly.  Tuberculosis (TB), just out of the top ten leading causes of death, was second 
only to HIV/AIDS as a leading cause of death due to a single infectious agent; 1.3 million 
people died from TB infection in 2012 [13].  On a smaller scale, cystic fibrosis (CF) affects 
70,000 people worldwide, but there is currently no cure for this deadly disease and the 
median age of survival is only 40 years [14].  In addition, asthma, although not a significant 
cause of death, affects over 235 million people worldwide and 25 million in the United States 
alone [15]. Pulmonary diseases account for a large economic burden in both healthcare costs 
and in productivity loss due to the symptoms and care needed for patients.  Thus, there is a 
significant and urgent need to continue the development of more effective therapies to 
prevent and combat these pulmonary diseases. 
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1.1.1 Chronic Obstructive Pulmonary Disorder  
COPD is characterized by persistent airflow limitation and has been associated with 
an enhanced chronic inflammatory response, often leading to the destruction of parenchymal 
tissue and small airway fibrosis [16]. Smoking is the primary cause of COPD but, in some 
countries, may also stem from exposure to high levels of outdoor and indoor air pollution 
[17].  In addition to symptoms disrupting workplace and home productivity, COPD has a 
significant economic health care burden estimated at $50 billion in the United States alone 
[18].  
Cessation of smoking is the most significant intervention to diminish the progression 
of COPD.  Because the disease symptoms and progression vary from patient to patient, 
personal tailored combinations of medicines are administered.  Beta2-agonists, 
anticholinergics, and inhaled corticosteroids are most often prescribed to COPD patients. 
 
1.1.2 Lower respiratory infections 
Lower respiratory infections can be categorized into either viral or bacterial causes.  
Ninety percent of lower respiratory infections are caused by viruses such as respiratory 
syncytial virus (RSV), influenza, adenovirus, coronavirus, and rhinovirus [19]. While there is 
no cure for viral infection, immunizations are recommended in order to arm the immune 
system and prevent infection.  Bacterial infection is often caused by Streptococcus 
pneumonia, Mycoplasma pneumonia or Bordetella pertussis [19, 20].  Antibiotics are 
administered for bacterial infections, but with the increase of antibiotic administration there 
is an increasing incidence of antibiotic resistance among bacteria.  Thus, there is a need to 
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better understand both the pathogenic and the host defense mechanisms to more effectively 
treat these bacterial infections.   
 
1.1.3  Lung Cancer 
Lung cancer has been the most prevalent type of cancer in the world for the past 
several decades.  It is also the most common cause of death from cancer worldwide, 
accounting for one in five of cancer related deaths (19.4% of total cancer deaths) [21].  There 
are two main types of lung cancer, non-small cell lung cancer (NSCLS), accounting for 85% 
of lung cancers, and small cell lung cancer (SCLC).  General lung cancer staging is based on 
the location and spread of the cancer and five-year survival rates are shown in Table 1.1.  
Early stage cancers are often difficult to detect: common symptoms such as coughing and 
fatigue are often attributed to other causes.  Because of this, most lung cancer patients are not 
diagnosed until the cancer has spread to regional lymph nodes or has metastasized to other 
organs.  
Table 1.1  5-Year Relative Survival of Lung Cancer Patients in the U.S. [22] 
Stage Cancer Locale 5-Year Relative Survival (%) 
Localized Cancer cells are localized to the lung 54.0 
Regional Cancer has spread to regional lymph nodes 26.5 
Distant Cancer has metastasized 4.0 
Unknown Unstaged 7.4 
 
The usual course of treatment, depending on the cancer stage and other patient related 
factors, involves surgery, radiation therapy, chemotherapy, and targeted therapies (i.e. 
monoclonal antibodies, proteins).  The chemotherapeutic drugs docetaxel, cisplatin, and 
paclitaxel are often used to treat lung cancer, but emerging immunotherapy drugs that 
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harness the immune system to fight cancer have shown great promise such as Merck’s 
pembrolizumab, a PD-1 inhibitor, which was just recently approved by the FDA.  Due to the 
ease of access to the lung and the ability for localized delivery, the inhaled route continues to 
be attractive for therapies targeting lung cancer treatment [23-28]. 
 
1.1.4  Tuberculosis  
Tuberculosis is a lethal infectious disease, infecting over eight million people and 
causing 1.3 million deaths in 2012 [13].   The TB infection is caused by the Mycobacterium 
tuberculosis bacterium.  Over two billion people in the world are estimated to be infected, 
and of those, 5-10%  will develop the clinical disease [29].  Although TB is not exclusive to 
infections of the lung, its primary deposition and resulting pathology occurs in the lung.  It is 
characterized by the formation of granulomas, which arise from aggregates of macrophages 
responding to persistent inflammatory stimuli [30, 31].  As these granulomas grow, they 
become surrounded by giant foam cells and epithelioid cells while other immune cells such 
as B and T cells, neutrophils, and dendritic cells are often seen within and surrounding the 
granuloma (Figure 1.1).  The granulomas harbor the bacteria, which continue to multiply 
slowly.  And as macrophages at the necrotic core of the mass begin to die they send signals 
to recruit more macrophages to the site. The recruited macrophages phagocytose the 
apoptotic cells and bacteria facilitating the formation of secondary granulomas.  Further 
progression of the disease may cause tissue damage by liquefying infected regions of the 
lung and ultimately spreading the infection to other parts of the body [32]. 
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Figure 1.1 Schematic of the tuberculous granuloma 
Figure reproduced from Ramakrishnan [31] with permission from Nature Publishing Group. 
 
Treatment of TB involves the administration of a combination of first line antibiotics 
(isoniazid, rifampicin, pyrazinamide, and ethambutol) over a six month period [33].  The 
length of treatment, multiple drug dosages, and potential toxic side effects often result in a 
reduction in patient compliance leading to relapses of infection and increased probability of 
drug resistance.   Second and even third line drugs have been developed to combat multi-
drug resistant instances of TB.  Inhaled antibiotic delivery has been investigated to mitigate 
some of the severe side effects of these potent TB drugs with promising results in animal 
studies [34].  Inhaled bacterial vaccines are also being developed [35].   
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1.1.5  Cystic Fibrosis 
Cystic fibrosis is a genetic disease in which a mutation occurs within the cystic 
fibrosis transmembrane conductance regulator (CFTR) gene.  CFTR regulates the chloride 
channel in epithelial cell membranes and primarily affects the lungs, pancreas, 
gastrointestinal tract, and sweat glands.  In CF patients, this mutation leads to thick mucus 
which can block the airways and provide an environment conducive to bacterial growth.  
Repeat infections over time can lead to sever lung damage.   
In addition to physical therapy, medicines such as antibiotics, mucolytics, and 
bronchodilators are given to decrease bacterial burden in the lung, loosen thick mucus 
buildup, and open up airways, respectively.  Gene delivery to the lungs has been explored by 
in many animal models, but has yet to be translated for human therapy [36].  Others have 
explored nanoparticle delivery of DNA for gene therapy applications in CF patients [37].  
 
1.1.6 Asthma 
Asthma is a chronic inflammatory disease characterized by bronchospasms that 
tighten the muscles around the airway thus restricting airflow.  For acute symptoms, asthma 
is often treated using short acting beta2-adrenoceptor agonists (SABA) such as salbutamol. 
The delivery target for SABA treatment is the airway smooth muscle cells [38].  For long-
term control of asthma, corticosteroids such as fluticasone and budesonide are administered 
for their anti-inflammatory effects.  Long acting beta2-agonists (LABAs) such as salmeterol 
and formoterol have a slower onset of action compared with SABAs, but have a longer 
duration of action of about 12 hours compared to 4-6 hours for SABAs.  Combination 
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therapies combining a corticosteroid with a LABA are often prescribed to prevent 
inflammation and widen the airways.   
Although asthma is manageable with current treatments, it still requires constant 
vigilance in one’s symptoms and often involves a dosing regimen of many drugs multiple 
times per day.  Thus, there is a need for the development of sustained-release therapies to 
decrease both the amount of different medications as well as the number of doses needed to 
control asthma symptoms while increasing patient compliance.   
  
1.2 Lung Physiology 
A fundamental understanding of lung physiology is needed in order to develop and 
deliver effective pulmonary drug delivery vehicles.  The lung can be separated into three 
main regions; the extrathoracic region which includes the nasal and oral airways, the 
conducting zone, and the respiratory zone (Figure 1.2) [39].  The airways in the lung consist 
of twenty-three generations of asymmetrical branching networks, with each subsequent 
branch decreasing in diameter [40].  The conducting zone covers the region from the trachea 
(G0) to the terminal bronchioles (G16) and is characterized bya layer ofmucus-producing 
cells and ciliated cells with a surface area of 2-3 m
2
.  The respiratory zone, where gas 
exchange takes place, begins from the respiratory bronchioles (G17) ends at the alveolus 
(G23) and is characterized by minimal surfactant coverage and a surface area of 102 m
2
 [41].   
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Figure 1.2 Schematics of the human respiratory system. 
Figure taken from Kleinstreuer (2008) [39] 
 
 
The cellular makeup of the lung epithelium between the conducting zone and the 
respiratory zone is significantly different and of noted importance for drug delivery 
applications.  In the conducting airways, the epithelium consists of mucus and ciliated cells 
(~ 58 µm tall) that form the mucociliary escalator.  There is a liquid layer on top of the 
epithelium which is approximately 8 µm in thickness in the upper airways.  The thickness of 
the cells and the mucus layer decreases progressively through each generation.  In the 
alveolar region, there is a less than 0.2 µm barrier between the airway and bloodstream 
(Figure 1.3). 
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Figure 1.3 Comparison of the lung epithelium at different sites within the lungs. 
Figure reproduced from Byron and Patton (2007) [1] with permission from Nature Publishing 
Group. 
 
Inhaled particulates that deposit in the conducting zone may be caught in the mucus 
layer and are swept out of the lungs via the mucociliary elevator.  Macrophages in the 
pericillary environment scavenge particles as well and aid in clearance.  Particles which land 
in the alveolar region are rapidly engulfed by one of the 12-14 alveolar macrophages (AM) 
patrolling each of the 500 million alveoli in the human lung [42].  Neutrophils are quickly 
recruited to the lung in response to microbes where they phagocytose and kill the invading 
pathogen through the production of proteases, reactive oxygen species (ROS) and reactive 
nitrogen species (RNS) [43].  They can also enhance further neutrophil recruitment with the 
release of cytokines (IL-6, TNFα, IL-1) as well as other chemical signals. Dendritic cells 
(DCs), key regulators of adaptive immunity, act as sentinels in the lung by recognizing and 
internalizing foreign antigens then transporting them into the draining mediastinal lymph 
nodes where the antigens are presented to naïve T cells [44].   
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Figure 1.4 Schematic representation of airway mucus layer and component cells. 
Ciliated and nonciliated epithelia (yellow) line the conducting airway surface with their 
basolateral surfaces interacting with the basal lamina (green). Basal cells (orange) are an 
important progenitor cell type. Submucosal glands are a major source of secreted liquid, host 
defense factors, and mucins. The mucus (gel) layer (purple) covers the periciliary fluid (sol) 
layer (blue) in which cilia are submerged. Figure and caption reproduced from Oakland 
(2012) [45] with permission from Nature Publishing Group. 
 
 
1.3 Physiological Barriers to Efficient Drug Delivery to the Lung 
The average human adult takes over 20,000 breaths a day, breathing in a considerable 
number of foreign particulates.  Because of this, the lung has developed highly efficient 
particle clearance mechanisms such as macrophage phagocytosis, mucociliary clearance, and 
metabolic degradation. A schematic of the factors that can affect drug deposition and 
clearance in the lung is shown in Figure 1.5.  The physiological clearance mechanisms, 
unfortunately, are non-discriminatory of enemy invaders intent on wreaking havoc in the 
body or of allied reinforcements looking to fortify the body’s defense system.  Thus, it is 
necessary to better understand the physiologic lung-particle interactions in order to design 
drug carriers that can overcome, or even utilize, the body’s defense mechanisms.  
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Macrophage clearance and mucociliary clearance are the primary focus of this work and will 
be described in more detail. 
    
Figure 1.5 Factors affecting drug deposition and clearance in the lung. 
Figure reproduced from El-Sherbiny (2011) [46] with permission from Springer Publishing. 
 
1.3.1 Mucociliary Clearance 
Mucus in the lung serves to trap inhaled particulates such as allergens, pollutants, and 
pathogens. Goblet cells are the mucus-producing cells of the lung and work in tandem with 
the ciliated cells to sweep the mucus upwards towards the trachea and out of the lung.  The 
primary components of mucus are the entangled and cross-linked mucin glycoproteins 
secreted by goblet cells and the seromucinous glands [47].  The regulation and production of 
these fibers along with the other components of mucus (salts, DNA, lipids, cells, proteins and 
water) is highly complex and the alteration of the balance of these components due to disease 
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states leads to rheological properties that may contribute to patient mortality and reduced 
therapeutic effect of inhaled drugs [48, 49].     
Mucociliary clearance can be avoided by targeting the site of deposition of a 
particulate delivery vehicle away from the mucociliary escalator.  This is accomplished by 
generating particles with aerodynamic diameters (da) between 1-5 µm which have been 
shown to deposit deep in the alveolar airspaces where there is minimal mucus coverage 
compared to the upper airways [50, 51].  Some approaches attempt to harness the highly 
adhesive properties of mucus by formulating their drug and/or carrier with mucoadhesives, 
such as chitosan and hydroxypropyl methyl-cellulose (HPMC) to increase absorption of a 
drug by increasing the residence time of the formulation at the site of absorption [52, 53].  
Others have developed particles with modified surface chemistries in order to reduce particle 
immobilization in mucus and allow further penetration of the particles through the mucus 
layer [54, 55]. 
 
 
1.3.2 Macrophage Clearance 
Upon delivery to the pulmonary region, particles of 1-5 µm in diameter are 
phagocytosed by alveolar macrophages [56, 57].  The importance and efficiency of alveolar 
macrophage clearance is supported by the half a billion AMs found in the human lung [1] 
making this one of the major obstacles to efficient drug delivery to the lung.  Avoidance of 
macrophage uptake may be preferred for aerosolized therapeutics targeted to the alveoli and 
associated epithelial cells as well as for systemic delivery [58].  This was shown in studies in 
which depletion of AMs by clodronate resulted in an increased pulmonary bioavailability of 
larger inhaled proteins such as IgG and human chorionic gonadotropin [56].  Because 
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particles with geometric diameters of 1-5 microns have been shown to be preferentially taken 
up by AMs [58, 59], large, porous particles [58] and swellable microparticles [60] were 
developed to deposit in the alveolar airspace while avoiding macrophage uptake due to their 
large (> 5 µm) geometric size.  On the other hand, the sequestration of bacteria in 
macrophages for diseases such as tuberculosis and pneumonia may make AMs prime targets 
for antibacterial delivery [61].  Targeted apoptosis of AMs has also been shown to lead to 
increased protection from M. tuberculosis infection and an enhanced Th1-mediated immune 
response [62].   
Modifying the surface chemistry of proteins and particulate drug carriers through 
PEGylation has been shown to increase steric stability and impart stealth properties [63].  
Adding PEG chains to the particle surface create a barrier that mitigates the adhesion of 
opsonins onto the particle and reduces recognition and phagocytosis by macrophages. These 
benefits have been demonstrated with multiple particle systems in vitro and in vivo [64-66].  
PEGylation of PLGA particles dosed in vitro to J774 murine alveolar macrophages showed a 
significant decrease in uptake compared to the unPEGylated particles [67].  Other coatings 
such as 1,2-dipalmitoylphophatidylcholine (DPPC), a major component of lung surfactant, 
on the surface of PLGA particles have also been shown to reduce uptake in alveolar 
macrophages in vitro [68].  Surendrakumar, et al. have shown that co-spray drying insulin 
and hyaluronic acid (HA) can extend the mean residence time of the insulin in the canine 
lung compared to spray dried insulin alone [69].   
In addition to particle size and surface properties, particle shape has also been shown 
to influence macrophage uptake kinetics.  The local particle shape at the point of attachment 
has been observed to influence the kinetics of particle uptake [70].   This is unsurprising as 
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phagocytosis is actin-dependent, and thus an energy-dependent, process.  The more actin 
remodeling that the cell must undergo in order to engulf a particle, the slower the rate of 
internalization.  A dimensionless parameter, Ω, has been developed to denote the local 
contact angle the cell membrane makes with the particle at the initial point of contact [70, 
71].  A local particle contact angle of Ω < 45° indicates that phagocytosis will be initiated 
while at Ω > 45° the macrophage will not initiate phagocytosis and may instead spread over 
the particle without engulfing it [70] (Figure 1.6).    
 
 
Figure 1.6 Schematic diagram of particle contact angle (Ω) influence on phagocytosis. 
T represents the average of tangential angles from θ = 0 to θ = π/2. Ω is the angle between T 
and cell membrane at the site of attachment, N.  Figure reproduced from Champion (2006) 
[71] and copyright © by the National Academy of Sciences. 
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Interestingly, Hutter et al. have shown that nanoparticle geometry can influence the type of 
cytokines released when taken up by microglial cells, the resident macrophages in the brain 
(Figure 1.7) [72]. 
 
Figure 1.7 Differential release of chemical mediators in response to nanoparticle 
geometry.   
Reprinted with permission from Albanese, A., E.A. Sykes, and W.C.W. Chan, Rough around 
the Edges: The Inflammatory Response of Microglial Cells to Spiky Nanoparticles. ACS 
Nano, 2010. 4(5): p. 2490-2493. Copyright 2010 American Chemical Society. [73] 
 
Research has shown that the aspect ratio of a particle may also affect uptake.  Work 
investigating the uptake of gold nanoparticles has shown that higher aspect ratio nanorods 
(1:3 and 1:5) are internalized less than spherical particles [74, 75].  However, Gratton et al. 
has shown that polymeric nanoparticles with a higher aspect ratio (1:3) are in fact 
internalized more quickly than nanoparticles of a similar volume but with an aspect ratio of 
1:1 [76].  These reports demonstrate the variability of findings that may depend on the 
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particle matrix, cell type, particle size, and particle shape, thus reinforcing the need for 
further elucidation of these complex particle-biological interactions.  With the various 
particle characteristics, such as size, shape and surface chemistry, being explored for inhaled 
therapeutics, can we systematically “build” a particle to test each of these characteristics and 
their effects on cellular uptake and residence time in the lung?   
 
1.4 Generation of Aerosols for Inhaled Drug Delivery 
1.4.1 Delivery Methods of Inhaled Aerosols  
 The development of inhaled therapies has been documented as far back as 1554 BC 
when the Egyptians vaporized the leaves of black henbane to treat those who had trouble 
breathing [77].  Since then, methods of delivering drugs to the lung have evolved from the 
inhalation of burning plant material over a fire to the development of complex devices with 
internals consisting of reservoirs for the active pharmaceutical ingredient (API) and multi-
stage aerosolization systems.  Current inhaler devices are categorized into three major 
systems:  nebulizers, propellant driven pressurized metered-dose inhalers (pMDIs), and dry 
powder inhalers (DPIs).  It has been shown that current asthma drug inhalers only achieve 
dose-delivery efficiencies of 10-30% in adults and 3-15% in children [39].  As such, there is 
a critical need to develop inhalers with increased dose efficiency.  
Nebulizers generate aerosolized mists by directing compressed air or ultrasonic 
atomization mechanisms at a reservoir of liquid drug generating dispersed liquid droplets 
[78].  The aerosolized mist is generated and inhaled for 10-20 minutes.  Due to the extended 
inhalation time of the aerosolized drug, higher doses are achieved with a nebulizer than with 
pMDIs or DPIs.  However, an external energy source is needed to aerosolize the liquid drug; 
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thus, nebulizers are often heavy, bulky, and power intensive.  Because of this, nebulizers are 
more commonly used in hospital and in-home settings.   
A pMDI device is more patient friendly as it is more portable than a nebulizer and 
each dose is administered in less than a minute.  The pMDI formulation consists of a liquid 
formulation of the API, a high vapor pressure propellant, and surfactants and other excipients 
that decrease drug-aerosol aggregates and lubricate the metering valves of the device.  It 
releases a metered dose of liquid drug at high pressure, emitting the drug in the form of 
heterogeneous droplets from the actuator mouthpiece.  Coordinated breathing and actuation 
of the drug by the patient is essential for achieving optimal dose-delivery to the lung.   
While nebulizers and pMDIs employ a liquid drug form, DPIs utilize solid drug 
particles in dry powder form.  DPIs are propellant free and breath-actuated which reduces the 
breathing and actuation coordination often needed with pMDIs.  The three major components 
of a DPI are the dry powder formulation of the API, an aerosolization mechanism, and a 
metering system.  The dry powder formulation for a DPI often consists of micronized drug 
and carrier excipients which are used to enhance drug aerosolization and increase the bulk 
volume of the powder for more uniform capsule filling.  Because a DPI is breath-actuated, it 
is not recommended for those with low levels of lung function and young children.  Dry 
powders are also sensitive to moisture which may affect the stability of the emitted drug 
aerosol, but new manufacturing and packaging technologies have increased the storage and 
reproducibility of DPIs.   
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1.4.2 Characterization of Inhaled Aerosols 
Particle size is an important parameter in the determination of dose deposition in the 
lung.  Aerosol particles (greater than 0.5 µm in geometric diameter)are characterized by their 
aerodynamic diameter, Da, which is defined as the diameter of a sphere (density 1 g/cm
3
) 
with the same settling velocity as a non-spherical particle.  Particles with a Da of 10 µm or 
larger will primarily deposit in the mouth, pharynx, and trachea.  Particles of 5-10 µm in size 
typically deposit in the large conducting airways of the lung.  Particles between 1-5 µm can 
deposit in the respiratory zone consisting of the smaller, lower bronchi and alveolar regions. 
Generating aerosols with an appropriate Da is essential for optimal therapeutic efficacy in the 
lung.   
Characterization of the aerodynamic diameter is analyzed using an Andersen cascade 
impactor (ACI), the current gold standard in industry for inhaler aerosol testing [79, 80].   
The ACI sizes particles based on inertial momentum through an eight-stage impactor.  
Particles are dispersed into the ACI and pulled through a series of stages with decreasing 
nozzle diameters with a vacuum.  Particle of certain cut-off diameters will impact on the 
collection plates of a stage while particles of smaller diameter will continue to follow the air 
flow around the collection plate and enter the subsequent stage through the nozzles (Figure 
1.8).  Aerosol particles are also characterized using an Aerodynamic Particle Sizer 
spectrometer (APS).  The APS sizes particles by utilizing a time-of-flight technique that 
measures the residence time of the particles in flow through a nozzle with two parallel lasers.  
The APS counts individual particles as they pass through the measurement zone where their 
aerodynamic diameter is determined.    
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Figure 1.8 Schematic of a cascade impactor.  
Figure reproduced from Son (2011) [80] with permission from Springer Publishing. 
 
1.4.3 Particle Fabrication Techniques for Inhaled Drugs 
Particle fabrication can be divided into two main categories, bottom-up and top-
down.  Bottom-up approaches to particle fabrication allow for the precursor particle 
components to increase in size via methods such as self-assembly, chemical synthesis, or 
colloidal aggregation.  Examples of bottom-up fabrication methods of particles investigated 
for pulmonary drug delivery and/or toxicology include carbon nanotubes [81, 82], gold 
nanoparticles [83], micelles [84], liposomes [85, 86], silica nanoparticles [87], polyplexes 
[88], and spray-dried particles [11].  Top-down fabrication approaches start with a bulk 
material and break it down into smaller particle sizes.  Common top-down particle 
fabrication methods include milling [89] and soft lithography [90].  Dry powder formulations 
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generated from conventional manufacturing techniques for pharmaceutical aerosols such as 
spray-drying (bottom-up) or milling (top-down) are shown in Figure 1.9 [91].   
 
Figure 1.9 SEM images of spray-dried particles (A) and milled particles (B). 
Images adapted from Senatore (2010) [92] and Zijlstra (2004) [93] and reprinted with 
permission. 
 
As seen in the figure, these powders exhibit a large polydisperse aerosol population 
and lack control over the resulting particle shape.  Thus, there remains a lack of 
understanding of the influence of particle shape and size on aerosol delivery to the lung.  
Top-down lithographic particle fabrication techniques can reproducibly generate 
monodisperse particle populations of many different sizes and shapes and is an emerging 
technique to better understand the effects of specific particle parameters in drug delivery. 
 
1.5 Particle Replication in Non-wetting Templates (PRINT) 
Particle Replication in Non-wetting Templates (PRINT) is a top-down 
nanofabrication technique which was inspired by the microelectronics industry and utilizes 
soft-lithography to produce calibration quality, monodisperse nano- and micro-particles with 
precise control over particle size, shape, composition, modulus, and surface chemistry [94-
97].   
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Figure 1.10 Schematic illustration of the PRINT process.   
(a) Features on a hard silicon master template are replicated with high fidelity (b) to obtain a 
soft, polymeric mold with micro- and nanocavities that can then be (c) filled with relevant 
particle matrix and (d) extracted out of the mold and onto a harvest array for (e) particle 
collection and purification. Figure and caption reproduced from Garcia (2012) [83]. 
 
Particle fabrication via PRINT is illustrated in Figure 1.10.  It is a multi-step process 
beginning with physically etching a silicon wafer with the intended shaped-pattern.  
Perfluoropolyether (PFPE) molds are generated by replication of the silicon master template 
resulting in a mold with precisely shaped cavities.  PFPE was used due to its very low surface 
energy, flexibility, UV transparency, nonswelling properties, and its ability to be 
photochemically cured [98].  Particle solutions are then contacted with the mold and 
spontaneously fill the cavities via capillary forces without wetting the area around the 
cavities preventing the interconnected “flash” layer from forming.  The material in the filled 
mold can then be solidified through a wide range of methods such as photochemical cross-
linking, evaporation, or crystallization.  The solidified particles are then transferred to harvest 
layer which can then be dissolved using appropriate solvents.  This results in a solution of 
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free particles that can then be lyophilized for storage or chemically modified as needed. 
Depending on the particle composition used, fluorescent dye may be incorporated into the 
particle matrix in order to track particles in vitro and in vivo.  Special monomers can be 
incorporated into the particle as well to provide function handles for the addition of targeting 
ligands and/or a PEG stealthing layer to tailor uptake by specific cell populations. 
Because of its mild processing conditions, aerosols consisting of a variety of small 
molecule drugs and sensitive biologics (siRNA, BSA, DNAse) can be fabricated into precise 
shapes with monodisperse particle populations (Figure 1.11).  Utilizing the plug-and-play 
characteristics of PRINT, applications in red blood cell mimics [99, 100], chemotherapeutic 
delivery [101, 102], and microneedle drug delivery [103] have also been explored.   
 
Figure 1.11 SEM micrographs of diverse PRINT aerosols.  
(a) BSA/Lactose 200 × 200nm cylinders; (b) IgG/Lactose10 μm pollen; (c) 30k PLGA 3 μm 
cylinders; (d) itraconazole 1.5 μm torus; (e) itraconazole 3 μm torus; (f) itraconazole 6 μm 
torus; (g) zanamivir 1.5 μm torus; (h) DNAse 1.5 μm torus; (i) siRNA 1.5 μm torus. Figure 
and caption reproduced from Garcia (2012) [90]. 
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1.6 Thesis Overview 
The goal of this thesis is to examine the influence of different particle parameters of 
potential drug carriers on physiological responses in the lung.  Utilizing PRINT technology, 
nano- and micron-sized particles were fabricated with precise shapes, sizes, compositions, 
and surface chemistries.  The versatility of PRINT allowed for the systematic tuning of 
particle characteristics in order to investigate the impact of these parameters on cell uptake 
and lung distribution.  Further, differential uptake was explored for potential implications in 
therapeutic applications. 
In Chapter 2, cross-linked hydrogels of different aerodynamically relevant non-
spherical shapes were fabricated and characterized.  PRINT allowed for the generation of 
interesting particle shapes such as pollen-mimicking geometries and ball-and-stick 
geometries with varying number of arms and purposeful asymmetry, none of which are 
accessible via common particle fabrication methods.  Because alveolar macrophages play a 
significant role in particle clearance, in vitro experiments investigating the effect of particle 
shape and size on macrophage uptake were performed.   
In Chapter 3, the effect of particles on the innate immune system was investigated.  
For use as drug delivery vehicles, particles dosed to the lung should not cause unintended 
inflammatory responses.  PLGA (poly(lactic-co-glycolic acid)) and PEG (poly(ethylene 
glycol)) PRINT particles were instilled into the lungs of mice and immunological outcomes 
were measured.  Particle residence time and cellular uptake in lung cells were also observed 
for both nano- and micro-particles. 
In Chapter 4, particle distribution and cellular uptake in the lung was explored with 
an additional emphasis on the effect of surface chemistry.  In these experiments, a more in 
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depth analysis of the physiological response to instilled particles was pursued to investigate 
both inflammatory effects as well as particle clearance by specific cell populations in the 
lung.   
In Chapter 5, a summary of the findings and future directions of this work is 
presented. 
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CHAPTER 2 
 
EFFECTS OF PARTICLE SHAPE AND SIZE ON ALVEOLAR MACROPHAGE 
UPTAKE 
 
2.1 Overview 
There is a significant unmet need in the delivery of respiratory drugs to target or de-
target macrophages depending on the desired site of action of various therapeutics.  Alveolar 
macrophages often present a significant barrier to efficient pulmonary drug delivery 
applications because of i) their rapid and undesirable clearance of certain deposited drugs in 
the lung whose site of action involves non-macrophage targets, like aerosolized therapeutics 
targeted to the alveoli and epithelial cells; or ii) by their protection and harboring of disease 
targets, such as infectious bacteria like tuberculosis, which makes it difficult to treat 
effectively.  There has been widespread interest in designing particles for use in dry powder 
inhalers that have the ability to target or de-target alveolar macrophages in order to increase 
their therapeutic index.  Using PRINT
®
, a top-down nano- and micro-molding particle 
fabrication technique based on soft lithography, we were able to generate unique micron-
sized particle geometries with aerodynamic diameters between 1-5 µm but with volumes that 
ranged between 5 – 45 µm3 which was achieved by controlling particle shapes.  Over two-
fold reduction in particle uptake by alveolar macrophages with selected shapes was observed 
indicating the potential for tailored avoidance of macrophage clearance in the lung.  Cell 
interactions with these shape-specific particles were further investigated using microscopy 
27 
 
techniques to gain a better understanding of how particle shape affects the kinetics of 
phagocytosis.  Integrating drug delivery design with particle geometry engineering in order 
to modulate phagocytic tendencies may lead to novel therapeutic and diagnostic paradigms 
for a wide range of diseases. 
 
  
2.2 Introduction 
Common particle fabrication techniques for pulmonary delivery, like self-assembled 
and spray dried methods, favor the formation of spherical particles which minimize surface 
energy and yield significant dispersions in particle sizes and shapes [9].  Indeed, the study of 
aerosols is complicated because of the heterogeneous nature of traditional particle fabrication 
technologies.  With the advent of PRINT (Particle Replication in Non-wetting Templates) 
technology and other lithographic particle fabrication methods, an added dimension of shape 
can be explored for both deposition and cell targeting properties of particle-based therapies.  
Additionally, PRINT allows for the precise control over many particle characteristics such as 
size, composition, porosity, modulus, and surface functionality [104, 105].  The ability to 
screen particles by altering one variable at a time may provide insights into the underlying 
fundamental mechanisms of drug delivery to the lung, potentially leading to the development 
of more efficient and effective drug delivery vehicles. 
The ease of access, large absorptive surface area, and reduced enzymatic activity of 
the lung make it an attractive target for both local and systemic drug delivery.  Inhaled 
aerosol treatments for local lung diseases such as chronic obstructive pulmonary disease 
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(COPD), pulmonary hypertension (PHT), asthma, cystic fibrosis (CF), and tuberculosis (TB) 
have been widely investigated [61, 106-108].  However, current aerosolized drugs often 
underperform therapeutically, owing to a variety of issues such as a polydisperse population 
of particle sizes, inefficient control of deposition in the lung, and a lack of efficient 
mechanisms for controlled release of the therapeutic.  In addition, drug particles must 
circumvent the lung’s highly efficient particle clearance mechanisms such as mucociliary 
transport, phagocytosis by macrophages [109], and rapid absorption of drug molecules into 
the systemic circulation [110].   
Mucociliary clearance can be reduced by delivering particles less than 5 µm in 
aerodynamic diameter, thereby avoiding particle deposition in the mucociliary escalator of 
the tracheobronchial region [51].  Upon delivery to the pulmonary region, particles are 
rapidly taken up by alveolar macrophages (AM) [56].  Avoidance of macrophage uptake may 
be preferred for aerosolized therapeutics targeted to the alveoli and epithelial cells as well as 
for systemic delivery [58].  This was shown in studies in which depletion of AMs by 
clodronate resulted in an increased pulmonary bioavailability of larger inhaled proteins such 
as IgG and human chorionic gonadotropin [56].  Because particles with geometric diameters 
of 1-5 microns have been shown to be preferentially taken up by AMs [58, 59], large, porous 
particles [58] and swellable microparticles [60] were developed to deposit in the alveolar 
airspace successfully avoiding macrophage uptake due to their large (> 5 µm) geometric size.  
However, the sequestering of bacteria in macrophages for diseases such as tuberculosis (TB) 
and pneumonia may make AMs prime targets for antibacterial delivery [61].  Targeted 
apoptosis of AMs has also been shown to lead to increased protection from M. tuberculosis 
infection and an enhanced Th1-mediated immune response [62].   
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Recent research concerning cellular internalization of particles has investigated the 
influence of geometry on cellular internalization and trafficking [70, 111, 112].  In vitro 
investigations into shape effects of polystyrene particles on macrophage phagocytosis have 
found that the local contact angle between the particle and the cell may play a role in the 
initiation of phagocytosis [70, 113].  Utilizing PRINT, we were able to synthesize unique 
geometric shapes with varying numbers of appendages and bearing distinct terminal shapes 
and sizes to further explore the role of shape on macrophage phagocytosis.  Due to the 
versatility of chemical composition enabled by the PRINT technology, particles composed of 
various polymers, chemotherapeutics, and sensitive biologics could be produced allowing 
defined therapeutic effects to be tuned for particular applications [100, 114, 115].  PRINT 
enables the synthesis of bio-inspired shapes such as pollen and bacteria, thereby allowing us 
to mimic the diversity of inhaled particles in order to screen characteristics relevant to 
overcoming the barriers to efficient drug delivery to the lung.     
Herein, we show that the geometry of distinctly shaped particles with similar 
aerodynamic diameters can influence the extent of alveolar macrophage phagocytosis.  This 
ability to target or de-target pulmonary macrophages upon administration of aerosolized drug 
particles may be used as a novel strategy for the design of efficient inhaled drug delivery 
systems.  
2.3 Materials and Methods 
PRINT Particle Fabrication 
Master templates of all the shapes tested were prepared using photolithography.  
Fluorocur PRINT molds were generated from silicon master templates of the particles 
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(Liquidia Technologies).  PRINT particles were composed of 96 wt. % poly(ethylene glycol) 
diacrylate (MW: 700), 2 wt. % fluorescein-O-acrylate, and 2 wt. % 2,2,-
diethoxyacetophenone.  This polymer mixture was drop-cast onto PRINT molds.  A 
polyvinylpyrrolidone (PVP)-coated poly(ethylene terephthalate) (PET) cover sheet was 
laminated on top of the mold to aid in homogenous spreading of the monomer solution across 
the mold.  The PVP cover sheet was then peeled away from the filled mold at the nip of a 
laminator, removing residual monomer and a filled mold with no connecting flash later.  The 
mold was then placed in a UV curing chamber, purged with nitrogen, and cured (λ=365 nm, 
power >20 mW/cm
2
) for 4 minutes in order to polymerize the monomer solution.  Cured 
particles were transferred out of the mold onto a polyvinyl alcohol (PVOH) – coated PET 
harvesting sheet by laminating the mold and harvesting sheet together and running them 
through a heated laminator nip.  The mold was then peeled off leaving free particles on the 
harvesting sheet.  Particles were collected from the harvesting sheet by bead harvesting with 
water.  After washing the particles 5 times with water, the particles were pelleted by 
centrifugation, the supernatant removed, and the pellet was resuspended in tert-butanol and 
flash frozen with liquid nitrogen.  The particles were lyophilized overnight to generate a dry 
powder. 
 
Zeta Potential Measurements 
The zeta potential of PRINT particles was measured in 30% (w/w) sucrose solution 
using a nano ZS Zetasizer (Malvern Instruments). 
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Aerodynamic Diameter Calculation 
Mass median aerodynamic diameters (MMADs) were calculated for each particle 
geometry using computational software developed in house.  Aerosol geometries, surface and 
volume meshes were defined using Gmsh software and discretized into appropriate triangles 
and tetrahedra.  Particle trajectories were then computed for aerosols settling based on a 
Stokes flow assumption by solving equations of motion using fourth order Runge-Kutta 
integration in time. From these computations, a dynamic shape factor (χ) was calculated, and 
subsequently, MMADs could be determined from the following equation: 
𝑀𝑀𝐴𝐷 = √(
6𝑉𝑝
𝜋
)
3
√(
𝜌𝑝
𝜒𝜌0
) 
where Vp is the particle volume, ρp is the density of the particle and ρ0 is a reference density. 
 
Uptake Experiments 
MH-S (ATCC) and RAW264.7 (ATCC) cell lines were used for the particle uptake 
experiments.  Cells were plated at 2 x 10
4
 cells/well in a 24-well plate 48 hours before 
dosing.  Particles were re-suspended in water and particle number counted with a 
hemacytometer.  Cells were dosed at a constant particle number (10 particles / cell) in media 
consisting of high glucose Dulbecco’s Modified Eagle Medium (DMEM) (Gibco) and 10% 
fetal bovine serum (FBS) and were incubated together from 0.5 to 24 hr (37°C, 5% CO2).  
After incubation, cells were washed with Dulbecco’s Phosphate Buffer Saline (PBS) solution 
and detached with trypsin (MH-S) or cell-scraped (RAW264.7).  The cells were then re-
suspended in an 0.2% trypan blue (Sigma) solution in PBS to quench extracellular 
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fluorescence.    The samples were analyzed by flow cytometry (CyAn ADP, Dako).  5,000 
cells were measured for each sample.  Two different particle batches were tested for all 
shapes and time points. 
 
Live Cell Imaging 
MH-S cells were plated at 4x10
4
 cells/well in a 0.17 mm Delta T dish (Fisher) 48 
hours before dosing.  Cells were then dosed at a particle concentration of 50 µg/mL in 
DMEM with 10% FBS and imaging was begun within 10 minutes of dosing.  An Olympus 
FlowView 500 confocal microscope was used to collect fluorescent and bright-field images 
every 5 minutes for one hour.  Consecutive 1-hour videos were made totaling 4 hours for one 
field of view.  The image files were then condensed into a video using Imaris (Bitplane) 
image processing software.  
 
Confocal Laser Scanning Microscopy 
MH-S cells were plated at 5 × 10
5
 cells on cover slips in 6-well dishes and grown for 
24 hours before dosing. Cells were treated with particles for 0.5 to 12 hours.  Cells were then 
washed with phosphate- buffered saline, pH 7.4(PBS) and fixed with 4% Para formaldehyde 
in PBS for 10 min at room temperature.  Cells were permeablized with 0.1% Triton –X100 in 
PBS for 3min and incubated in phalloidin (Alexa-555) (Molecular Probes) for one hour at 
room temperature in the dark. Coverslips were washed three times with PBS and mounted 
with FluorSave reagent (Calbiochem).  Samples were then analyzed by confocal microscopy.  
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Confocal images were acquired using a Zeiss 710 laser scanning confocal imaging system 
(Zeiss) fluorescence microscope fitted with a PlanApo 60× oil objective (Zeiss).   
 
 
Scanning Electron Microscopy 
MH-S cells were seeded at 20k cells/well on glass slides placed in each well of 24-
well plates and allowed to adhere overnight.  The cells were dosed at a particle number of 8 
particles/cell and were incubated for time points between 0.5 and 4 hours.  After incubation, 
cells were fixed with 4% paraformaldehyde (PFA) at room temperature and dehydrated with 
washes of increasing ethanol concentration.  Cells were then run under critical point drying 
(CPD) conditions.  After drying, cells were sputter-coated with gold-palladium for SEM 
imaging. 
 
Modulus Testing 
The modulus of the cross-linked PEG700-DA hydrogels was measured using 
polymerized macroscopic “dog-bone”-shaped bulk samples.  The samples were tested on an 
Instron 5566 Universal Testing Machine (Instron) with a strain rate of 10 mm/min.   
 
2.4 Results and Discussion 
PRINT provides the opportunity to produce geometrically diverse particles that have 
similar aerodynamic diameters, but result in very different macrophage uptake kinetics.  
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Screening geometric characteristics of particles that influence macrophage uptake can be 
done rapidly using PRINT because the same fabrication method can be used to generate all 
of the shapes studied with consistent particle composition and other physical properties.  By 
adding aerodynamic shape characteristics, such as fenestrations, to the particle, we were able 
to generate particles of larger volume with the same mass median aerodynamic diameters 
(MMAD) as particles with smaller volumes.  
 
2.4.1 Fabrication of PRINT Particles 
A collection of non-spherical shapes was fabricated using PRINT to create near 
monodisperse and geometrically precise populations of particles.  Aerodynamically inspired 
shapes, such as pollen, were designed to investigate aerosolization efficacy, pulmonary 
deposition and cellular internalization properties.  These hydrogel micro-particles were 
primarily composed of cross-linked poly(ethylene glycol) and have calculated aerodynamic 
diameters between 1-5 µm, the ideal size for pulmonary deposition.  Four particle 
characteristics were used to describe the shapes examined: (1) the shape diameter (SD), 
which is the minimum diameter of a circumscribed circle around the particle (and is the 
number that precedes the shape name throughout the manuscript to differentiate different 
sizes of the same geometry); (2) the minimum feature size (MFS), which is the diameter of 
the smallest distinct geometry of the shape; (3) the particle volume; and (4) the aerodynamic 
diameter (MMAD) of the particle.    Three distinct families of shapes were examined: (1) a 
toroid (donut)-shaped series (SDs = 3 µm, and 6 µm; Figure 2.1 A,B); (2) a pollen shape 
(SD=11.68 µm, MFS=10 µm; Figure 2.1 C); and (3) a ball-and-stick series [7.77 µm 
lollipop, SD=7.77 µm, MFS=4 µm (Figure 2.1 D); 10.24 µm helicopter, SD=10.24 µm, 
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MFS=1.6 µm, (Fig 1E); 9.54 µm l-dumbbell, SD=9.54 , MFS=2.5 µm (Figure 2.1 F); 12.3 
µm v-boomerang, SD=12.3 µm, MFS= 2.25 µm (Figure 2.1 G)].  Scanning electron 
microscopy was used to confirm the dimensions of the particles.  The measured zeta potential 
of all particle geometries was approximately -20 mV.   
Table 2.1 Volumes, dimensions, and Mass Median Aerodynamic Diameter (MMAD) of 
shaped particles 
Shape Total Volume (µm
3
) Min. Feature Size (µm) Calc. MMAD (µm) 
3 µm Donut 5.03 3 1.73 
10.24 µm Helicopter 6.91 1.6 1.68 
12.3 µm V-Boomerang 7.75 2.25 1.75 
9.54 µm L-dumbbell 9.22 2.5 1.95 
7.77 µm Lollipop 12.30 1 2.25 
11.68 µm Pollen 35.60 10 2.74 
6 µm Donut 40.67 6 3.26 
 
 
 
 
 
Figure 2.1 Scanning electron micrographs of PRINT particles.  
(A) 7.77 µmm Lollipop. (B) 10.24 µm Helicopter. (C) 12.3 µm V-Boomerang. (D) 9.54 µm 
L-dumbbell. (E) 11.68 µm Pollen. (F) 6 µm Donut. (G) 3 µm Donut.  (Scale bar: 5 µm) 
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2.4.2 Kinetics of Particle Uptake as a Function of Shape and Size 
Flow cytometry was used to investigate effects of particle geometry on macrophage 
internalization.  MH-S murine alveolar macrophages were dosed with a constant particle 
number (10 particles/ cell) and uptake was measured from 0.5 to 24 hours at five time points.  
Kinetics of cellular internalization was analyzed using a flow cytometry method in which 
membrane-bound and internalized particles were differentiated using fluorescence quenching 
with trypan blue [116].   For particle shapes that were internalized efficiently, a rapid 
increase in particle-positive cells was observed within the first eight hours after which 
intracellular particle concentration remained constant (Figure 2.2 A).  The internalization 
percentage of particles that were less efficiently internalized also leveled out after eight 
hours, but the initial internalization kinetics were significantly slower.   By utilizing 
knowledge from previous studies on macrophage internalization based on size and volume 
[58, 59, 112], we were able to generate rationally designed geometric shapes that 
encompassed certain characteristics to either increase or decrease macrophage phagocytosis.  
It was observed that different shapes with aerodynamic diameters of 2.6 ± 0.7 µm could be 
tailored to have over two-fold difference in macrophage internalization (Figure 2.2 B).  
Phagocytosis of these PRINT particles was predominantly influenced by volume, as shapes 
of similar volume had similar internalization patterns.  After 24 hours, MH-S  cells with 
internalized particles of all of the ball-and-stick series of shapes with volumes of 7-12 µm
3
 
was approximately 40% while the internalization of 6 µm donut and 11.68 µm pollen 
geometries,  which have volumes greater than 35 µm
3
, leveled out at 20%.  This significant 
reduction in macrophage uptake is promising for pulmonary therapies which would benefit 
from enhanced residence time and minimal drug clearance from the lung.  The same trends 
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were also seen when RAW264.7 murine leukaemic macrophages were dosed similarly 
(Figure 2.3) indicating that the findings from this work may potentially be utilized in 
applications targeting or de-targeting macrophages in other parts of the body.   These results 
demonstrate the influence of particle geometry on macrophage uptake and the ability of 
PRINT to generate particles of similar aerodynamic diameter but vastly different geometric 
dimensions.   
 
Figure 2.2 Internalization profile of particles in MH-S cells (24 hrs) 
 (A) Particle uptake timecourse of all PRINT shapes dosed.  (B) Comparison of particle 
uptake between shapes with similar aerodynamic diameters (2.6 ± 0.7 µm). 
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Figure 2.3 Internalization profile of particles in RAW264.7 cells (8 hrs) 
 
2.4.3 Particle Orientation/Geometric Effects in Macrophage Phagocytosis 
Macrophages in the lung constantly survey a numerous and diverse population of 
particulates.  Research into how the cell acts on these particles has been limited by the lack of 
fabrication methods for generating non-spherically shaped particles.   Budding yeast has been 
extensively used to investigate the proteins and cellular mechanisms involved in 
phagocytosis [117].  Champion, et al. stretched polystyrene particles to understand how local 
particle shape may influence the initiation of phagocytosis [118].  The unique shapes of these 
PRINT particles allow us to examine how additional geometric features such as asymmetry, 
appendages, angles, fenestrations, and size affect particle internalization by macrophages. 
Previous literature has shown that particles with maximal diameters of 2 µm had the 
highest percentage of particles internalized from initial particle number dosed [59].  Thus, it 
is interesting to note that, regardless of volume, all of the shapes with distinct minimum 
feature sizes less than or equal to 3 µm showed similar macrophage uptake from the flow 
cytometry data.  The ball-and-stick series of shapes included geometries with variable 
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number of arms, angle lengths, and end terminal diameter in order to investigate how certain 
geometric features may influence macrophage uptake.   
To more clearly examine geometric influences on macrophage uptake, fluorescent 
microscopy and scanning electron microscopy (SEM) techniques were utilized to capture 
cell-particle interactions at early time points (Figure 2.4).  The local particle shape at the 
point of attachment has been observed to influence the kinetics of particle uptake [70].   This 
is unsurprising as phagocytosis is actin-dependent, and thus an energy-dependent, process.  
The more actin remodeling that the cell must undergo in order to engulf a particle will slow 
the rate of internalization.  A dimensionless parameter, Ω , has been developed to denote the 
local contact angle the cell membrane makes with the particle at the initial point of contact 
[70, 71]. When one cell is associated with two or more particles, the particle in which the 
local particle contact angle (Ω < 45°) is more favorable towards phagocytosis is observed to 
be further engulfed (Figure 2.4 A, D) [70].  However, since these micrographs are of fixed 
cells, the order and timeline of cell attachment to the particle cannot be definitively 
determined.   
Interestingly, we observed active phagocytosis of these PEG particles when Ω was 
larger than 45° (Figure 2.4 B, E).  Previous studies have shown that both IgG-opsonized and 
non-opsonized particles with Ω > 45° induced spreading of the cell membrane but did not 
induce phagocytosis [70].  The two most studied pathways of macrophage particle 
internalization are Fc receptor (FcR)- and complement-mediated phagocytosis; however, 
since these particles were not opsonized the exact mechanism by which they are 
phagocytosed is not defined.  Complement-mediated phagocytosis involves particles 
“sinking” into the membrane [119, 120] while FcR-mediated phagocytosis, on the other 
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hand, extends the phagocytic cup around the particle before drawing the engulfed particle 
into the body of the cell [121, 122].  Since complement-mediated phagocytosis involves 
allowing the particle to sink into the membrane rather than totally enclosing it with actin 
filaments, the strict dependence on local contact angle as a determinant for internalization 
should be loosened.  It was observed that a majority of particles associated with cells were 
raised above the plane of the surface as the cell drew it into the membrane (Figure 2.4 C, F).  
This may allow the cell to “wrap” around the particle and initiate phagocytosis rather than 
just spreading along the flat side of the particle.  However, it may be noted that most particles 
observed in the process of being internalized did have Ω < 45° which is more favorable for 
phagocytosis. 
 
Figure 2.4 Micrographs of MH-S cells 
Cell association with shaped PEG particles depicting local particle angle effects on 
phagocytosis (1 hour timepoint). (A) 9.54 µm L-dumbbells, (D, F) 6 µm donuts, (B, C) 11.68 
µm pollen, (E) 10.24 µm helicopter. Scale bar: 10 µm (A, C, D, F), 20 µm (B), 5 µm (E) 
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To extend these observations, we were interested in identifying any trends in particle 
internalization characteristics when a macrophage is faced with two different geometries on 
the same particle.  With the “ball” end having a diameter of 4 µm and the “stick” end having 
a diameter of 1 µm, the lollipop shape offered a unique test of how particle geometry may 
dictate the cellular mechanisms of phagocytosis.  From the flow cytometry data, the lollipops 
had similar internalization kinetics to the rest of the ball-and-stick series indicating that 
having one end significantly larger than another may not affect overall kinetics in 
macrophage internalization.  However, from fluorescent microscopy analysis it was observed 
that at early time points the macrophages had a preference for the narrow end of the lollipop 
particles during initiation of particle internalization (Figure 2.5).  Because the cells are 
washed with PBS before fixation, unattached or loosely held particles are cleared away.  This 
data suggests that the cell may have a better grip on the 1 µm “stick” end of the lollipops 
because it initiates phagocytosis (actin remodeling) faster than if it first took hold of the 4 µm 
“ball” end which requires more time for actin polymerization around the particle although it 
is not known whether the cell will manipulate the particle as it is drawing it into the cell 
membrane.  This data may be useful in designing particles that de-target macrophages by 
incorporating larger feature sizes.   
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Figure 2.5 Particle orientation at early time points of phagocytosis 
(A) Determination of particle internalization orientation using fluorescent microscopy 
(Orientation labels – S: stick, B: ball, L: sideways, I: fully internalized, U: Undetermined).  
(B) Graph of lollipop particle internalization orientation at 0.5 hours in MH-S macrophages 
(n=3 groups; 100 particles/group).  Corresponding SEM images of particle orientation also 
shown.   
 
The effect of angled geometries on cell interactions with the particle was visualized 
using live cell imaging.  We hypothesized that the internalization kinetics of a particle would 
decrease when phagocytosis is initiated at the vertex versus at the terminal end of an 
appendage.  Initial studies with live video microscopy of 9.54 µm L-dumbbells interactions 
with macrophages demonstrated that there may be a difference in uptake kinetics dependent 
on where the cell first contacts the particle (Figure 2.6).  Notice that the particle first 
contacted by the cell on  the “ball” section (labeled A) is fully internalized while the particle 
contacted in the middle of the particle at theangled “stick” section (labeled B) is still mostly 
external to the cell membrane and may be a result of the increased contact angle at that point.   
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Figure 2.6 Time-lapse of particle internalization by macrophages 
Notice that the particle first contacted by the cell on “ball” section is fully internalized while 
the particle contacted at the angled “stick” section is still attached to the outside of the cell 
membrane.  (Scale bar: 10 µm) 
 
Phagocytosis of curved budding yeast has been studied with Dictyostelium cells in 
which it was found that the cells scan for concave or convex regions and can switch between 
actin polymerization and depolymerization to fully engulf, release, or cleave the particle 
[123].  From these observations, it was hypothesized that the 10.24 µm helicopters would 
have slightly slower internalization kinetics than the other ball-and-stick shapes due to the 
120° angle between each arm.  Most of the helicopters had phagocytosis initialized at the 
terminal end of one of the arms, thus, as the cell membrane approaches the “Y” of the shape 
it encounters a wide angle (240°) which would require more actin polymerization to fully 
engulf the particle (Figure 2.7).   The flow cytometry data, however, does not show a 
difference in cellular internalization among the ball-and-stick family of shapes indicating that 
the arm angle of the 10.24 µm helicopter may not affect phagocytosis kinetics as 
significantly as overall particle volume or minimum feature size.     
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Figure 2.7 Illustration of particle angles encountered by macrophages 
The actin cup must expand as it reaches the “Y” angle of the helicopter shape in order to 
complete phagocytosis. (Scale bar: 10 µm) 
 
It is interesting to note that the cells exerted enough force to visibly stretch and bend 
these PRINT particles (Figure 2.8) which have a modulus measured around 6 MPa. Previous 
literature has shown that more rigid particles are preferentially phagocytosed over softer 
particles [124], and flexible, worm-like particles both in vitro and in vivo have been observed 
to reduce macrophage uptake [125, 126]. Recently, low-modulus (7.8 kPa) red blood cell 
(RBC) mimics fabricated using the PRINT technique have demonstrated extended circulation 
times in vivo likely due to their ability to circumvent the body’s physical filtration barriers 
[100].  Reduced macrophage uptake of these RBC-like particles may also explain the 
increased time of circulation, thus, by decreasing the modulus of these aerodynamically-
shaped particles one may be able to further reduce macrophage uptake. 
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Figure 2.8 Micrographs depicting the ability of macrophages to deform highly cross-
linked PEG particles. (A) V-boomerangs being stretched into a more linear particle by two 
cells.  (B) Helicopter shape being drawn towards the cell membrane. 
 
2.5 Conclusion 
We wanted to investigate both the macro- and micro- implications of particle shape in 
targeting or de-targeting macrophage uptake.  Using PRINT technology, particles with 
similar aerodynamic diameters but very different geometries were fabricated.  From the flow 
cytometry data we show that macrophage internalization can be reduced over two-fold by 
increasing the volume of the particle through manipulation of particle shapes.  Since particles 
with similar MMAD’s deposit in the same area of the lung, the ability to tailor particles to 
avoid macrophage uptake for specific therapies should increase the efficiency of pulmonary 
drug delivery, and may improve the safety and therapeutic index of a given drug therapy.  In 
order to more fully understand shape dynamics on macrophage uptake we looked at the 
influence of individual geometric features.  Previous studies on shape have shown that local 
particle contact angle influences the initiation of phagocytosis. We found that while 
internalization kinetics were correlated to Ω, local contact angles greater than 45° did not 
necessarily prevent the initiation of phagocytosis.  The inclusion of angles or asymmetry in 
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the particles was shown to have an influence on macrophage uptake.  These studies 
demonstrate the capacity of PRINT to develop a toolbox of particle shapes that can be used 
to better understand the cellular mechanisms responsible for these observations.   
Because the PRINT fabrication method allows for particle compositions of pure drug 
and other biodegradable components [115], different therapeutics can be incorporated into 
these geometries and shape-dependent efficacy can be further investigated.  We hope that by 
applying the knowledge from fundamental biological studies of macrophage phagocytosis to 
pulmonary delivery applications we can design more efficient drug carriers to the lung. 
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CHAPTER 3 
 
ANALYSIS OF THE MURINE IMMUNE RESPONSE TO PULMONARY 
DELIVERY OF PRECISELY FABRICATED NANO- AND MICROSCALE 
PARTICLES
1
 
 
3.1 Overview 
The pulmonary route of administration for inhaled therapeutics has been actively 
explored due to its non-invasive nature, the ease of access to the lung, and its large absorptive 
surface area.  However, the physiological effects of particulate delivery to the lung have not 
yet been fully defined for materials commonly utilized in inhaled particle compositions.  In 
this work, Particle Replication in Non-wetting Templates (PRINT) was used to fabricate 
particles on the nano- and micro-scale with precisely defined parameters in particle shape, 
size, and matrix. These calibration quality particles were then instilled into the lungs of mice 
to investigate the murine innate immune response as a function of different particle 
parameters.  Both poly(lactic-co-glycolic acid) (PLGA) and polyethylene glycol (PEG) 
particles did not induce the release of pro-inflammatory cytokines or inflammasome 
activation in vitro and in vivo.  All particle sizes tested (80x320 nm, 1 µm, 1.5 µm, and 6 µm 
in diameter) were shown to remain in the lung out to seven days without triggering host 
immunity which is promising for use of these particles in sustained and localized pulmonary 
drug delivery. 
                                                          
1 Adapted from:  Roberts RA, Shen T, Allen IC, Hasan W, DeSimone JM, et al. (2013) Analysis of the Murine 
Immune Response to Pulmonary Delivery of Precisely Fabricated Nano- and Microscale Particles. PLoS 
ONE 8(4): e62115. doi:10.1371/journal.pone.0062115 
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3.2 Introduction 
The development of nano- and micro-particles as therapeutic vehicles for the 
treatment of disease has demonstrated the potent ability of these carriers to influence 
physiological responses.  From genetic modulation by delivery of small interfering RNA to 
enhanced chemotherapeutic responses to even multi-functional imaging diagnostics, the use 
of particle formulations has had a transformative effect on pharmaceutical approaches 
towards disease therapies [127-129].  Another emerging aspect of therapeutic materials 
delivery is that of immunoengineering in which modulation of the intrinsic defense systems 
in the body may instruct specific immunological responses to influence the pathological 
outcomes of disease states [130].    Studies on programming antibody responses, enhancing 
humoral responses with nanoparticle vaccines, and increasing antibody responses to particle-
delivered antigens have shown great promise in being able to direct immunological outcomes 
[131-133].  These advances are opening up the field not only to improved vaccines, but also 
to autoimmune disease, organ transplantation, diabetes, and cancer immunotherapies [134-
136].   
In order to fully realize the potential of particulate drug carriers for localized and 
sustained release systems in the lung, safety as well as efficacy must be investigated.  A 
particle designed to circumvent lung clearance mechanisms may enhance local drug delivery 
and improve efficacy; yet, if it also initiates inflammatory or other host immune responses its 
safety profile would undermine its intended function and use as a therapeutic intervention.  
Particles developed for immunotherapy, or the treatment of a disease by engendering an 
appropriate immune response may be more efficacious with design parameters that can 
49 
 
activate the appropriate immune response or tailor the degree of the adaptive immune 
response.   
Not much is yet known on how specific particle parameters may influence the host 
immune response, thus, it is appropriate to investigate the potential particle design 
characteristics that may activate these responses.  Particle Replication in Non-wetting 
Templates (PRINT) is a top-down nanofabrication technique that utilizes soft-lithography to 
produce calibration quality, monodisperse nano- and micro-particles with precise control 
over particle size, shape, composition, modulus, and surface chemistry [94-97]. Thus, 
specific particle parameters can be probed to investigate their roles in influencing biological 
responses upon administration. In this work, in vitro and in vivo assays were used to 
investigate the murine inflammatory response to PLGA- and PEG-based particles.  We find 
that PRINT nano- and micro-particles do not prompt systemic or localized inflammatory 
responses.  This demonstrates that rational design strategies of therapeutic modalities can 
help develop an essential fundamental understanding of the biological effects of these 
particulate carriers without the concern of anti-vector effects.   
 
3.3 Materials and Methods 
Particle Materials 
Poly(ethylene glycol) diacrylate (Mn 700) (PEG700DA), 2-aminoetheyl methacrylate 
hydrochloride (AEM), Diphenyl (2,4,6-trimethylbenzoyl)phosphine oxide (TPO), and poly 
lactic co-glycolic acid (PLGA; 85:15 lactic acid/glycolic acid, MW= 55 000 g/mol) were 
purchased from Sigma-Aldrich.  Tetraethylene glycol monoacrylate (HP4A) was synthesized 
in-house as previously described [137]. Thermo Scientific Dylight 650 maleimide, PTFE 
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syringe filters (13mm membrane, 0.220 μm pore size), dimethylformamide (DMF), 
triethanolamine (TEA), pyridine, sterile water, borate buffer (pH 8.6), Dulbecco’s phosphate 
buffered saline (DPBS) (pH 7.4), 1X phosphate buffered saline (PBS) (pH 7.4), acetic 
anhydride and methanol were obtained from Fisher Scientific. Conventional filters (2 μm) 
were purchased from Agilent. Polyvinyl alcohol (Mw 2000) (PVOH) was purchased from 
Acros Organics. Liquidia Technologies provided all PRINT molds used in these studies (80 
nm x 320 nm, 1μm cylinder, 1.5μm and 6μm donuts). 
 
PRINT PLGA Particle Fabrication 
The fabrication process for PLGA PRINT particles has been described previously 
[114, 138].  Briefly, pre-particle solutions of PLGA were prepared in a 4:16:1 solvent 
mixture of DMSO:DMF:water and cast onto a poly(ethylene terephthalate) (PET) sheet and a 
Mayer rod was used to draw a thin polymer film.  A PRINT mold with the desired features 
(80x320 nm or 1 µm cylinder shapes) was placed on top of the pre-particle polymer film and 
run through a heated laminator to allow filling of the mold.  These particles were then cooled 
below the polymer glass transition temperature then transferred from the mold onto a harvest 
layer of poly(vinyl alcohol) (PVOH) by passing the filled mold/PVOH sheets through a 
heated laminator.  Particles were collected from the harvest layer via bead harvesting using 
water to dissolve away the PVOH resulting in free particles.   
 
PRINT Hydrogel Fabrication 
PRINT hydrogel fabrication used a preparticle solution of 67.5 wt.% HP4A, 20 wt.% 
AEM (functional monomer), 10 wt.% PEG700DA (crosslinker), 1 wt.% TPO (photoinitiator), 
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and 1.5 wt.% Dylight 650 maleimide.  This solution was dissolved in methanol at 3.5 wt% 
solids and cast onto a PET sheet with a Mayer rod.  The appropriate mold was then placed in 
contact with the pre-particle film and filled by running through a heated laminator in which 
the mold and PET sheet were split as the sheets emerged from the nip.  The filled mold was 
then cured with ultra-violet radiation (395 nm) and a PVOH harvesting layer was used to 
transfer the particles out of the mold.  Water was used to dissolved away the PVOH and 
collect the free particles. 
The micron-sized (1.5 µm and 6 µm) particles were fabricated using a dropcast 
method.  The preparticle solution was spread directly onto the mold and a PET sheet was 
laminated on top of the mold by running through a heated laminator.  The PET sheet was 
removed and the mold was UV with a UV LED lamp for 30 seconds.  Particles were 
transferred out of the mold using a Luvitec
®
 (BASF SE) harvest sheet and particles were 
again collected with water.   
 
Particle Characterization 
Particle concentrations were determined using thermogravimetric analysis (TGA) 
(TA Instruments Q5000).  Scanning electron microscopy was used to visualize the harvested 
particles (Hitachi S-4700 scanning electron microscope).   
 
In vitro Confocal Analysis of Hydrogel Particle Uptake 
MH-S murine alveolar macrophages were plated in complete DMEM at 20,000 cells 
per well in 8-well chamber slides (LabTek) 48 hours prior to treatment with particles. 
Particles were resuspended in DMEM at 20 μg/mL and 300 μL of particle solution were 
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added to each well. Particles were incubated with cells at 37°C for 4 hours. Cells were then 
washed twice with PBS and cells fixed with 4% Paraformaldehyde (PFA) solution and later 
stained with Alexa Fluor 488 Phalloidin (Invitrogen) and DAPI (Vectashield, Vector Labs). 
Fluorescent imaging of stained cells was performed on a Zeiss 710 laser scanning confocal 
imaging system (Zeiss). 
 
In vitro Inflammation Assays 
Bone marrow macrophages (BMMs) were isolated as described previously [139] 
from the femurs of C57Bl/6 and BALB/c mice.  Cells were cultured for six days in DMEM 
with 10% FBS, L-Glutamine, pen/strep, and 20% L929 media.  Adherent cells were plated at 
200,000 cells per well in a 96-well plate 24 hours prior to particle treatment.  Control cells 
were primed with LPS (50 ng/mL) 24 hours prior to treatment to provide signal 1 for 
inflammasome activation.  Particles were then dosed to the cells and supernatant were 
collected 24 hours post-dose.  ELISAs of IL-1β, TNF-α, and IL-6 were used to analyze 
cytokine response.  Lactate dehydrogenase release was used to measure cytotoxicity.   
 
Assessment of Airway Inflammation 
C57Bl/6 mice (10-12 wk old) were anesthetized by isofluorane inhalation and 
particles were instilled orotracheally with 50 µg particles/50 µL PBS (n=5).  Instillation of 
PBS (50 µL) or LPS (20 µg/50µL PBS) were given as negative and positive controls, 
respectively.  Mice were euthanized two or seven days after installation.  Blood was collected 
by cardiac puncture, and the serum was separated by centrifugation and utilized for ELISA 
analysis of inflammatory cytokines.  Bronchoalveolar lavage fluid (BALF) was also collected 
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and both the cells and supernatants were kept for further analysis.  BALF cellularity was 
assessed using a hemocytometer and cellular composition was analyzed by cytospin of BALF 
aliquots onto slides and staining with Diff-Quik for differential cell counts.  After BALF 
collection, lungs were harvested and stored in 10% buffered formalin. 
 
Histopathological Analysis 
After H&E staining of 5 µm sections of fixed lungs, inflammation was determined by 
scoring as described previously [140, 141].  Briefly, histology images were evaluated on 
inflammatory parameters (mononuclear cell infiltration, polymorphonuclear cell infiltration, 
airway epithelial cell hyperplasia/injury, extravasation, perivascular cuffing, and estimated 
percentage of lung with inflammation) and given a score between 0 (absent) to 3 (severe).   
 
Particle Uptake in BALF 
Cells from the BALF were seeded onto 8-well chamber slides and fixed with 2% 
paraformaldehyde.  Cells were stained for actin (Phalloidin 488) and nuclei (DAPI).  Particle 
(Dylight 650) uptake was then analyzed by counting the number of cells with particles in five 
distinct fields of view.  
  
Statistical Analysis 
GraphPad Prism 5 software was used to identify statistical significance.  Student’s 
two-tailed t-test was used for single data point comparisons while Analysis of Variance 
(ANOVA) was used for multiple comparisons.  A p-value less than 0.05 was considered 
statistically significant. 
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3.4 Results and Discussion 
3.4.1 PRINT enables the fabrication of monodisperse and homogenous particles 
Utilizing PRINT technology to fabricate monodisperse particles of precisely defined 
matrix, shape, and size allowed us to address which particle parameters may influence 
inflammatory immune responses in mice.  Literature has described how size and shape may 
affect biological processes and outcomes such as cellular uptake of particles or vaccine 
delivery [76, 142].  Thus, particles spanning from 80x320 nm to 6 µm in diameter were 
generated to investigate sizes that were biologically relevant.  The measured size and zeta 
potential of these particles are shown in Figure 3.1A and C.  The polydispersity index (PDI) 
is a reflection of the heterogeneity in a particle population, and the PDIs shown indicate a 
nearly monodisperse population. The micron-sized particles were not analyzed for size by 
DLS due to their propensity for settling very quickly.  SEM images were used to determine 
the size of the micron-sized particles as well as further visualize the monodisperse character 
of the particle population as a whole (Figure 3.1 B, D).  All particle surface charges were 
also measured to be negative.  Particle uptake by MH-S alveolar macrophages was performed 
on the hydrogel particles to validate particle uptake in a pulmonary immune cell population 
(Figure 3.1 E). 
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Figure 3.1 PRINT Particle Characterization 
A) Dynamic light scattering (DLS) and zeta potential measurements of PLGA particles used 
in studies. Particle charge decreases with increasing size. B) Scanning electron microscope 
(SEM) images of PLGA particles. C) PEG particle composition and characterization. D) 
SEM of PEG particles. E) Confocal images of hydrogel particle uptake in MH-S alveolar 
macrophage cells after 4 hours of treatment. Scale bar is 50μm. Figure and caption 
reproduced from Roberts (2012) [143]. 
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3.4.2 PLGA particles do not induce inflammation by bone-marrow-derived macrophages 
While the efficacy and diagnostic power of nanoparticles has been comprehensively 
explored, the immune response to these nanomaterials has not yet been fully characterized.  
The innate immune system is responsible for initiating a swift response after identification of 
foreign material in the body.  This response is characterized by the release of cytokines and 
other soluble protein messengers that recruit additional immune cells to the area to help with 
defense and host repair [144].  Environmental toxicologists have studied the role of 
particulates in inducing inflammation in the lung, often for industrial and air pollutants [145, 
146].  Much of the literature indicates that there is not yet clear correlation between the 
particle’s physical properties and the resulting inflammatory response, however, it has been 
shown that certain particle compositions such as titanium dioxide and silica dioxide trigger 
inflammation while zinc oxide nanoparticles do not [147, 148].  These results indicate the 
sensitive immunological influence of the size, shape, and matrix of the particle. 
PLGA and PEG particles were dosed to bone marrow-derived macrophages from 
C57Bl/6 mice in vitro to assess the immune response of these particles.  Pro-inflammatory 
cytokines TNF-α, IL-6, and IL-1β were analyzed by ELISA from the cell supernatant.  At 
both the 5 and 24 hour time points, no detectable levels of any of the tested cytokines were 
seen (Figure 3.2).  Lipopolysaccharide (LPS) was used as a positive control for the release of 
inflammatory cytokines.     
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Figure 3.2 PRINT particles do not cause inflammation in bone marrow-derived 
macrophages from BALB/c or C57BL/6 mice 
Overnight stimulation with a panel of PRINT PLGA and hydrogel particles (PEG) at 
100μg/mL does not cause TNF-α, IL-6, or IL-1β release from bone marrow-derived 
macrophages from C57BL/6 mice as measured by ELISA. Figure and caption adapted from 
Roberts (2012) [143]. 
 
 
3.4.3 PLGA particles do not induce lung inflammation 
The lung was chosen to probe the inflammatory influence of the PRINT particles 
because of its clearly defined markers of inflammation and its therapeutic relevance for 
diseases such as asthma, allergies, COPD, and TB [149, 150].  In addition, the lung has been 
characterized as a “hub” where lymphocytes undergo gene modulation to direct them to a 
specific location in the body [151].  With both local drug delivery and immunomodulation a 
goal of particulate delivery to the lung, testing the physiological effects in this organ of 
interest would allow for a better understanding of the role of specific particle parameters on 
the inflammatory pathway. 
Although PLGA is approved by the F.D.A., there is disagreement in literature on the 
inflammatory potential of PLGA in vivo, with both positive and negative outcomes being 
reported [152-155].  In this study, we found that instilled PLGA particles into the lung do not 
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induce lung inflammation.  BALF cellularity was the same for both the PBS and PLGA 
treated mice, indicating no additional cell recruitment (Figure 3.3 A).  As expected, LPS-
treated mice resulted in increased cellularity, and, in particular, an increase in the monocyte 
and neutrophil populations. In particle-treated mice, no significant recruitment of specific 
immune cells was shown (Figure 3.3 B).  Analysis of lung histopathology of the main 
bronchi of the left lobe was used as another method to determine lung inflammation (Figure 
3.3 C,D).  No cell infiltration was seen in the particle-treated mice while the LPS-treated 
mice showed a significant recruitment of leukocytes in the lung.  BALF assessments of 
cytokine levels also showed that there was no significant release of IL-1β (Figure 3.3 E) or 
IL-6 (Figure 3.3 F).  Serum measurements for these cytokines and TNF-α were also 
undetectable for particle-treated mice (data not shown).   
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Figure 3.3 80x320 nm PLGA particles do not cause lung inflammation in mice. 
Mice were challenged with either 50μg of 80x320nm PLGA particles or 20μg LPS i.t. and 
airway inflammation was assessed 48 hours post-challenge. A) Total cellularity of 
bronchoalveolar lavage fluid (BALF) in treated C57BL/6 mice is no different after 48 hours 
than PBS-treated mice and is significantly less than the inflammatory cell recruitment seen in 
LPS-treated mice. B) PLGA particle treatment does not induce any appreciable immune cell 
recruitment to the lungs of mice, as opposed to the heightened levels of monocytes and 
neutrophils seen in the lungs of LPS-treated mice. C) Histopathology revealed no significant 
differences in lung architecture between PBS- and 80x320nm PLGA particle-treated mice. 
This is in stark contrast to the airway occlusion and significant innate immune cell 
recruitment seen in LPS-treated mice. D) Histopathology scoring confirmed that no 
significant differences were seen between the lungs of PBS and PLGA particle treated mice. 
E-F) The increased lung levels of pro-inflammatory IL-1β and IL-6 seen in LPS-treated mice 
is not found in PLGA-treated mice. PBS, n=3; 80x320nm PLGA particle-treated, n=5; LPS-
treated, n=3. ND = Not Detected. * = p< 0.05, *** = p<0.001. Experiments were performed 
using 3-5 mice per group. Data shown are representative of at least two independent 
experiments. Figure and caption reproduced from Roberts (2012) [143]. 
 
 
3.4.4 PEG particles remain in the lung for 7 days without causing lung inflammation 
Particles dosed to the lung were labeled with a fluorescent dye to facilitate confocal 
analysis of particle uptake in BALF cells.  The hydrogel particles fabricated had particles 
sizes of 80x320 nm, 1.5 µm and 6 µm diameters as shown in Figure 3.1.  Using the same 
methodology as with the PLGA particles, the PEG particles also showed no increase in cell 
recruitment in the BALF at two and seven days post dose (Figure 3.4 A-D).  Lung 
histopathology also showed no increases in cell infiltration (Figure 3.4 E, F). 
Interestingly, the 6 µm particles could be seen in the H&E stained lungs of multiple 
mice at both two and seven days post-challenge without showing overt signs of inflammation 
(Figure 3.5 A, B). Because of the lack of immune cell recruitment and tissue disruption 
around the particles, this may suggest that these particles are immunologically inert and can 
remain in the alveolar space for out to seven days.  Since the smaller particles (80x320 nm 
and 1.5 µm) were too small to visualize on the histology samples, BALF cells were imaged 
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to analyze particle uptake.  BALF cells contained particles of all sizes at both two and seven 
days post-instillation (Figure 3.5 C,D,F,G) with fewer cells taking up the larger 6 µm 
particles (Figure 3.5 E).  This may be due to the fact that particles were instilled by mass, 
thus, a larger number of the smaller particles will be dosed compared to the larger particles.  
Particle size and its effect on macrophage phagocytosis may also play a role in this decrease 
in uptake.  BALF and serum samples were also tested for IL-1β, IL-6, and TNF-α cytokines 
and no detectable levels were seen at both the two and seven day time points (data not 
shown).  This data again suggests that these particles are immunologically inert and can 
remain in the lung for at least seven days. 
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Figure 3.4 Hydrogel particles do not cause lung inflammation in mice. 
Mice were challenged with 50μg of hydrogel particles (80x320nm, 1.5μm, or 6.0 μm donuts) 
i.t. and airway inflammation was assessed 48 hours and 7 days post-challenge. A) BALF 
analysis indicated no increased cellularity 48 hours after hydrogel particle treatment, whereas 
a significant cellular influx was seen in LPS-treated controls. B) At 48 hours, BALF cellular 
composition does not show any significant trend for immune cell recruitment in hydrogel 
particle-treated mice. C-D) BALF cellularity and composition was not significantly 
augmented seven days after hydrogel particle treatment. E) Histopathology analysis revealed 
no significant differences in lung architecture between PBS- and hydrogel particle-treated 
mice at either 2 or 7 days post-treatment. F) Histopathology scoring confirmed that no 
significant differences were seen between the lungs of PBS and hydrogel particle treated 
mice at any time points. ***=p<0.001. Experiments were performed using 2-5 mice per 
group. Data shown are representative of at least two independent experiments.  Figure and 
caption reproduced from Roberts (2012) [143]. 
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Figure 3.5 Hydrogel particles remain in the lungs for multiple days without overt signs 
of inflammation. 
A) 6μm hydrogel particles (denoted by red arrows) are visible in the alveolar spaces 2 days 
after intratracheal installation. Lower insets are a magnified view of black bounding box. 
PBS treated mice are shown as control. B) Multiple 6μm hydrogel particles (denoted by 
black bounding box and red arrows) are visible in the alveolar spaces 7 days after 
intratracheal installation. C) Two days after treatment with hydrogel particles, BALF cells 
were stained and visualized for particle uptake via epifluorescence microscopy. Particles 
(Dylight 650, red); nuclei (DAPI, blue); F-actin (Phalloidin 488, green). D) Magnified views 
of BALF cells taking up hydrogel particles as denoted by white bounding boxes in Figure C. 
E) Quantification of particle uptake indicates smaller particles are more readily taken up in 
BALF cells than larger particles. F) All types of hydrogel particles can still be seen in BALF 
cells seven days after treatment, though there is a marked decrease in the number of particles 
present as compared to the 2 day time point. G) Magnified views of BALF cells taking up 
hydrogel particles 7 days after treatment as denoted by white bounding boxes in Figure C. 
Scale bar is 20μm. Data shown are representative of at least two independent experiments.  
Figure and caption reproduced from Roberts (2012) [143]. 
 
 
3.5 Conclusions 
Utilizing PRINT technology to generate particles of defined matrices, shapes, and 
sizes allowed the exploration of how different particle parameters may influence the immune 
response in the lung.  The resulting data indicates that both PLGA and PEG particles do not 
cause the release of inflammatory cytokines in vitro and in vivo, and that size also does not 
affect its immunological response.  That the PEG hydrogel particles were also seen in the 
lung out to seven days without signs of overt inflammation may indicate that they may be 
promising drug depot systems for sustained-release therapeutics.   
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CHAPTER 4 
 
DISTRIBUTION AND CELLULAR UPTAKE OF PEGYLATED POLYMERIC 
PARTICLES IN THE LUNG 
 
4.1 Overview 
Bridging the gaps between particle engineering, environmental health sciences, 
biology, and medicine will enable us to develop more efficient drug delivery vehicles by 
increasing our fundamental knowledge and understanding of the physiological outcomes of 
particulate delivery to the lung.  Utilizing Particle Replication in Non-wetting Template 
(PRINT) technology to fabricate particles on both the nano- and micro-scale with precisely 
defined shapes and compositions allows the exploration of the effects and importance of 
certain design parameters for local lung delivery of drug carriers.  In this study, polymeric 
hydrogel PRINT particles ranging from 80 nm to 6 µm in diameter were fabricated and 
modified with a surface layer of polyethylene glycol (PEG) and instilled into the lungs of 
mice. The size and surface modification of these particles can significantly affect uptake and 
retention by certain cell populations in the lung, thus allowing for potential sustained and 
cell-specific targeted delivery of therapeutics.  In addition, these particles were shown to 
reside in the lung out to twenty-eight days without inducing a significant inflammatory 
cytokine response. These results indicate that this platform is a promising and flexible system 
for testing and developing particles of specific design parameters towards more efficient drug 
carriers to the lung. 
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4.2 Introduction 
The study of particles in the lung spans several different fields of research.  Research 
in environmental health science studies the effects of environmental particulates, such as 
diesel exhaust particles and TiO2 particles, on lung injury, inflammatory responses and 
cellular clearance mechanisms in the lung. [3-8]  In pharmaceutical particle engineering, the 
technology of formulating and characterizing aerodynamically relevant particles for drug 
delivery to the lung is an area of high interest in both administration (e.g. dry powder inhalers 
and nebulizers) and therapeutic efficacy.[9-11] In medicine and physiology, the 
pharmacodynamics and pharmacokinetic effects of the drug molecule itself as well as how 
the disease states affects particle deposition and drug release are investigated.[1, 12]  
Integrating the methodology and knowledge from these various particle research areas will 
allow for a better understanding of specific design parameters important for the development 
of more safe and efficient drug delivery vehicles to the lung.  
Particle Replication in Non-Wetting Templates (PRINT) technology is itself a 
product of the synergistic merger between research in the microelectronics industry, polymer 
chemistry, and pharmaceutical sciences. It is a top-down lithography-based particle 
fabrication process that allows for the precise control over many particle characteristics such 
as size, shape, composition, porosity, modulus, and surface functionality.  Utilizing the plug-
and-play characteristics of PRINT, applications in red blood cell mimics [99, 100], 
chemotherapeutic delivery [101, 102], and microneedle drug delivery [103] have been 
explored.  For pulmonary applications, the ability to generate monodisperse populations of 
particles of a variety of geometries, matrices, and surface properties can be used to explore 
particle deposition properties based on particle shape [156], enhancement of drug delivery 
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from dry powder inhalers (DPIs) [90], and the physiological responses of particulate delivery 
to the lung. [143]   
Much remains to be explored of the in vivo cellular fate and inflammatory response to 
micro- and nano-particles composed of relatively inert polymers, such as poly(ethylene) 
glycol (PEG), often used for in drug delivery applications. In addition, there is a significant 
unmet need in the delivery of respiratory drugs to target or de-target cells in the lung 
depending on the desired site of action of various therapeutics.  Alveolar macrophages often 
present a significant barrier to efficient pulmonary drug delivery applications because of i) 
their sequestration and undesirable clearance of certain deposited drug particles in the lung 
whose site of action involves non-macrophage targets, like aerosolized therapeutics targeted 
to the alveoli and epithelial cells [57, 157] or ii) by their protection and harboring of disease 
targets, such as infectious bacteria like tuberculosis, which makes it difficult to treat 
effectively. [61]  Because particles with geometric diameters of 1-5 microns have been 
shown to be preferentially taken up by AMs [58, 59], large, porous particles [58] and 
swellable microparticles [60] were developed to deposit in the alveolar airspace and 
successfully avoid macrophage uptake due to their large (> 5 µm) geometric size.  
PEGylation of particles has been shown to reduce uptake by macrophages in systemic 
circulation, [158, 159] and coating of particles with the phospholipid 1,2-
dipalmitoylphosphatidylcholine (DPPC) was shown to reduce uptake in alveolar 
macrophages [160].  Physicochemical particle properties targeting macrophages have also 
been explored for enhancing host defense and regulating immune responses [161].  Dendritic 
cell uptake of particles containing an antigen may be advantageous for vaccine applications 
or immunomodulation therapies [162, 163]. Thus, the ability to screen particles by altering 
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one variable at a time should provide insights into the underlying fundamental mechanisms 
of particle uptake and clearance in the lung, which may progress towards an efficient 
delivery vehicle for sustained therapeutics in the lung. 
In this study, non-spherical polymeric hydrogel PRINT particles ranging from 80 nm 
to 6 µm in diameter were fabricated and surface modified with PEG.  These particles were 
then instilled into the lungs of mice and particle uptake and residence time in the lung was 
determined by flow cytometry and confocal microscopy.  In addition, the induction of 
inflammatory cytokines and recruitment of inflammatory cells to the lung upon particle 
delivery to the lung was investigated.  We show that dendritic cells in the lung and the BALF 
have distinct particle uptake preferences from that of macrophages, thus shedding light on the 
potential to target specific cellular subtypes in the lung by both surface chemistry and shape 
and size.  PEGylated particles were shown to reside in the lung out to twenty-eight days post-
dose demonstrating the potential for their use as delivery vehicles for sustained release 
therapeutics. 
 
4.3 Materials and Methods 
Fabrication of PEGylated Hydrogel PRINT Particles 
Particles were composed of 10% PEG700DA (cross-linker) (Sigma), 67% hydroxyl-
tetraethylene glycol monoacrylate (HP4A, monomer), 20% 2-aminoethyl methacrylate 
hydrochloride (AEM), 2% fluorescent dye (Dylight 650 Maleimide, Thermo Fisher), and 1% 
2,4,6-Trimethylbenzoyl-diphenyl-phosphineoxide (TPO, photoinitiator) (Sigma) by weight.   
This pre-particle solution was filled into a Fluorocur mold of the intended geometric shape 
and cross-linked in a UV curing chamber (λ=365 nm).  Particles were then transferred from 
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the filled mold onto a polyvinyl alcohol (PVOH) harvest layer.  Water was used to dissolve 
away the harvesting layer and free particles were collected.  PEG5k-succinimidyl 
carboxymethyl ester (PEG5k-SCM) was reacted with the amine functional handles resulting 
in a layer of PEG on the particle surface.[65] Both PEGylated and unPEGylated particles 
were then succinylated to quench any remaining free amine groups. 
 
Particle Characterization 
Geometric particle dimensions were measured by SEM analysis.  Particle zeta 
potential was measured using a Zetasizer Nano ZS (Malvern Instruments, Ltd.).  Particle 
aerodynamic diameter was measured using an Anderson Cascade Impactor (ACI) as 
described previously [156].  
 
Fluorescent Microscopy of In vitro Macrophage Uptake 
MH-S, a mouse alveolar macrophage cell line, (ATCC) was used for particle uptake 
experiments.  Cells were plated at 4 x 10
4
 cells/well in 8-well chamber slides (LabTek) 48 
hours before particle addition.  Cells were dosed with 25 µg particles in media consisting of 
high glucose Dulbecco’s Modified Eagle Medium (DMEM) (Gibco) and 10% fetal bovine 
serum (FBS).   Particles were incubated on the cells for 4 hours at 37°C with 5% CO2.  After 
incubation, cells were washed with Dulbecco’s Phosphate Buffer Saline (PBS) solution and 
fixed with 4% paraformaldehyde (PFA) solution.  Staining of actin (Alexa Fluor 555, 
Invitrogen) and DAPI (Vectashield, Vector Labs) of fixed cells was then performed.  
Fluorescent imaging of stained cells was performed on a Zeiss 710 laser scanning confocal 
microscope (Zeiss).   
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In vivo Lung Instillation 
To assess PRINT particle uptake in the lungs of mice, 8-10 week old female C57Bl/6 
mice (Jackson Laboratories) were anesthetized with isofluorane and 50 µL particle solution 
was orotracheally administered.  Particles were dosed at 50 µg per mouse in PBS solution.  
Administration of 50 µL PBS or 20 µg/50 µL lipopolysaccharide (LPS) served as negative 
and positive controls, respectively. At timepoints of one, seven, and twenty-eight days post-
particle dose, mice were euthanized and bronchoalveolar lavage fluid (BALF) was collected 
and the whole lung was excised.  O.C.T. (Tissue-Tek)-filled lungs of one to two mice per 
timepoint for each particle treatment was also collected and frozen for fluorescent lung tissue 
staining.    
 
Flow Cytometry Analysis 
Cells collected from BALF and single cell suspensions collected form homogenized 
whole lung were stained with a panel of fluorescent antibodies for flow cytometric analysis 
of particle uptake and cell populations.  The following antibodies were used for staining 
(BioLegend): CD45-PacBlue, CD11c-PE, MHCII-PE-Cy7, F4/80-BV605, Ly6-G-AF700.  
Cells were fixed with 4% PFA in PBS after staining and kept at 4°C until analysis.  Flow 
cytometry data was collected on the LSRII flow cytometer (BD Biosciences) and analyzed 
using FlowJo software. 
 
Cytokine Analysis 
ELISA kits for IL-6 (BD Biosciences) and MIP-2 (R & D Systems) were used to 
measure cytokine release in BALF supernatant. 
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Fluorescent Lung Tissue Staining 
Frozen lung was sliced into 7 µm thick sections, fixed with acetone, and fluorescently 
stained for phalloidin (Alexa Fluor 555 Phalloidin, Molecular Probes), CD11c (AF888 anti-
mouse CD11c, BioLegend), and cell nuclei (DAPI, Thermo Scientific).  Images were 
obtained on the Zeiss 710 confocal microscope. 
 
4.4 Results 
4.4.1 Fabrication and Characterization of PEGylated Hydrogel PRINT Particles 
Three different particle shapes, 80x320 nm, 1.5 µm donuts, and 6 µm donuts 
composed of PEG700-DA and with amine-functional handles were fabricated using the 
PRINT method.  SEM images show the monodispersity of the fabricated hydrogel particles 
(Figure 4.1).  Methoxy-PEG5k-SCM was then conjugated to these particles (designated 
80x320P, 1.5P, 6P) to provide a stealthing PEG layer on the surface.  Any remaining free 
amine groups were quenched with succinic acid.  Particles that were not PEGylated, 
(designated 80x320U, 1.5U, 6U), were also quenched with succinic acid so that all particle 
groups would have a comparable negative surface charge.  The particles were then 
characterized by surface area, volume, aerodynamic diameter and surface charge (Table 4.1).   
 
Figure 4.1 SEM images of PRINT hydrogel particles 
(A) 80x320 nm, (B) 1.5 µm donut, (C) 6 µm donut 
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Table 4.1 Particle characterization of surface are (SA), volume (Vol), aerodynamic 
diameter and charge. 
 SA (µm
2
) Vol (µm
3
) Aerodynamic Dia. (µm) Zeta Potential (mV) 
Particle    UnPEGylated PEGylated 
80x320 nm 0.097 .0018 --- -34.7 -28.5 
1.5 µm Donut 5.655 0.79 1.11 -25.3 -32.3 
6 µm Donut 88.593 40.68 3.26 -5.6 -31.3 
 
 
4.4.2 PEGylation of particles significantly reduces uptake by macrophages in vitro 
To confirm the surface modification of the particles with a PEG layer, particles with 
and without PEG surface modification were incubated in vitro with MH-S mouse alveolar 
macrophages at a dose of 25 µg / 40k cells. Cells were fixed and stained for fluorescent 
confocal microscopy 4 hours after particle dose.  As seen in the confocal images (Figure 
4.2), PEGylation significantly reduced particle association in macrophages for all particle 
sizes tested.  As expected, the macrophages most readily internalized the unPEGylated 1.5 
µm donuts compared to the other two particle sizes as particles with geometric diameters of 
1-5 microns have been shown to be preferentially taken up by alveolar macrophages.   
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Figure 4.2 Particles dosed to MH-S cells at 25 µg/40 k cells and imaged 4 hours post-
dose. Particles (red), Nuclei (blue), Actin (green) 
 
4.4.3 Particle effects on cell populations and cytokine response in the lung 
Relative cell populations of macrophages (Mɸ), dendritic cells (DCs), and 
granulocytes in the whole lung and bronchoalveolar lavage fluid (BALF) were analyzed by 
flow cytometry to determine the effect of particle administration on cell recruitment in the 
lung (Figure 4.3).  Macrophages constituted the major cell type in the BALF, ranging 
between 85-99% of the total (Figure 4.3A).  DC percentages of total cells ranged from 1-5% 
(Figure 4.3B). Granulocyte populations were negligible (Figure 4.3C) in the saline and 
particle-treated mice.  The macrophage population was observed to change based on the size 
and surface modification of the particle dosed.   One day after particle instillation, it was 
observed that in the 80x320 nm and 1.5 µm donut treated mice, the unPEGylated particles 
had a mean macrophage population that was 5% and 10% lower, respectively, than their 
PEGylated counterparts while there was no statistical difference between the 6 µm donuts of 
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different surface modifications.  This trend continues out to day seven for the 80x320 nm 
sized particles. The LPS-treated mice had a significant influx of granulocytes in the BALF at 
24 hours post-dose such that the relative number of macrophages was decreased by 2-fold.  
Interestingly, although the percentage of DC’s in the BALF was low; there was a 
surface modification effect on the DC population at 24 hours post-dose that compliments the 
macrophage population trends.  More specifically, the percentage of DC’s was 2.5 and 3.8 
fold lower in the mice treated with the PEGylated particles verses the unPEGylated particles 
of the 80x320 nm and 1.5 µm donut shapes, respectively.  This difference only occurs at the 
day one timepoint, as no other significant differences in the DC cell populations between 
particle-treated mice occurs in the BALF collected on days seven and twenty-eight.  
However, there was a significant decrease in DC populations in the saline control mice 
compared to the particle-treated mice.  Only the 80x320P and 1.5P particles had similar DC 
levels (~ 1%) as the saline treated mice, while the 80x320U, 1.5U, 6U, and 6P particles had 
about a 4-fold increase in the DC population.  This observation suggests that both surface 
modification and particle size may play a role in the appearance of DCs in the BALF.   
In the whole lung, macrophages, dendritic cells, and granulocytes typically make up 
less than 20% of the cell population as endothelial, epithelial, and interstitial cells comprise a 
greater majority of lung cells (Figure 4.3 D-F).  In these experiments, the macrophage, DC, 
and granulocyte populations ranged from 5-20%, 5-15%, and 1-6% of the total whole lung 
cell population, respectively.  Interestingly, the surface modification effect seen on the DCs 
in the BALF is not replicated in the whole lung.  After 24 hours the particle-dosed mice had 
50% fewer macrophages in the lung than the saline-dosed mice which may indicate 
macrophage recruitment to the airspace to assist in particle clearance.  Similar to the BALF, 
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LPS-treated mice had a significant influx of granulocytes in the lung and the relative number 
of macrophages in the lung tissue was decreased by 8-fold.  Slight increases in the 
granulocyte population in both BALF and lung was observed with the 6 µm particles at one 
day post-dose, but reverted back to saline levels at later time points.  No other statistical 
difference between cell populations of the particle-treated mice was observed at one, seven, 
or twenty-eight days in the whole lung. 
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Figure 4.3 Relative populations of macrophages, dendritic cells (DC) and granulocytes 
BALF(A-C) and whole lung (D-F) as determined by flow cytometry analysis. Saline and LPS 
cell populations analyzed only at 1 and 7 days post-dose. (* p < 0.05,  *** p < 0.0001) 
 
Lung architecture and cell infiltration was also analyzed by lung histology (Figure 
4.4).  Cell infiltration was noticeable only in the unPEGylated 6 µm donuts one day post 
dose.  All other particles doses at one, seven, and twenty-eight days showed no change in 
lung architecture or infiltration of granulocytes to the lung. 
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Figure 4.4 H&E stained lung tissue 24 hours after particle dose. (2x magnification) 
 
Previous studies from Chapter 3 have shown that PRINT PEG hydrogel particles do 
not induce an inflammatory response of TNF-α, IL-1β,and IL-6 production in the lung out to 
14 days. [143]  In this work, IL-6 and MIP-2, a mouse macrophage inflammatory protein that 
may play a key role in neutrophil recruitment, was analyzed in BALF collected at one, seven, 
and twenty-eight days after particle administration.  By ELISA, detectable levels of IL-6 and 
MIP-2 were only seen one day post particle instillation (Figure 4.5).  This cytokine data is 
indicative of the immune cell recruitment seen in the flow cytometry analysis of the cell 
populations in the BALF: both the 80x320U and the 6U dosed mice had slightly elevated 
granulocyte levels at day one compared to saline.  Interestingly, histopathology on these 
samples shows no significant neutrophil recruitment to the lungs.    
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Figure 4.5 IL-6 and MIP-2 cytokine levels measured from BALF 24 hours post-
instillation. 
 
4.4.4 Surface modification of particles affects particle retention time and cellular uptake in  
the lung 
To determine particle size and surface modification effects on particle retention time 
and cellular uptake in the lung, flow cytometry was run on collected BALF and whole lung 
cells.  Different cell populations were determined by gating based on CD45, Ly6G, F4/80, 
CD11c, and MHCII surface markers.  The particles contained Dylight 650 dye, thus allowing 
uptake in specific cell populations to be determined by flow cytometry analysis as well.  The 
percentage of particle positive cells within a population was determined for BALF 
macrophages (Figure 4.6 A), lung macrophages (Figure 4.6 D), and lung DC’s (Figure 4.6 
G).  The median fluorescence intensity (MFI), a measure of the volume of particles taken up 
by each particle positive cell, was also graphed (Figure 4.6 B, E, and H).  In addition, the 
total fluorescence was calculated by multiplying the number of positive particle cells by the 
MFI in order to give an overall view of the total volume of particles internalized (Figures 4.6 
C, F, and I).  
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Unlike what was seen in vitro, macrophages in the BALF were non-discriminating of 
surface modification for the smaller 1.5 µm donuts and 80x320 nm particles at one day post 
instillation with over 80% of macrophages having taken up particles. Yet, at day 28, the 
PEGylated 80x320 nm particles were present in 60% of BALF macrophages versus only 
20% for their unPEGylated counterparts indicating a surface modification response to 
particle uptake and/or clearance.  With the larger 6 µm donuts, the macrophages had 
preferential uptake of the unPEGylated particles at one and seven days post-dose with no 
uptake seen at day 28.  Because particles were dosed by mass and not by number, the 
reduced percentage of particle positive cells for the 6 µm donut instilled mice may be due to 
a reduced surface area coverage of the particles in the lung.  In addition, the significantly 
larger volume of the 6 µm donut may also play a role in reduced uptake by macrophages.  
The MFI data better normalizes the volume of particles taken up by each particle 
positive cell.  In BALF macrophages (Figure 4.6 B), the median fluorescence intensity of the 
cells that were associated with the 6 µm donuts was 2-3 times greater than that of the other 
shapes at one day post-dose, indicating a larger mass of particles per cell.  After one day, 
there was a 1.6-fold reduction in MFI of the 80x320P particle positive macrophages 
compared to that of the 80x320U and a 3-fold reduction in MFI of the 1.5 P particles 
compared to the 1.5 U particles after 1 day.  This indicates that a greater number of 
unPEGylated particles were initially taken up by macrophages, thus, surface modification 
may affect the propensity and degree of particle uptake in vivo.  At day twenty-eight, the MFI 
levels of all particles were extremely low, yet, as mentioned previously, over 60% of 
macrophages in the BALF were particle positive for PEGylated 80x320 nm particles.  This 
may indicate that macrophage clearance and/or turnover rates can be affected by surface 
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modification as well, with the addition of a PEG layer being able to prolong particle 
residence time in the lung.   
The total fluorescence data for BALF macrophages (Figure 4.6 C), shows a clear 
pattern in the effects of surface modification on particle uptake.  At 24 hours post-dose, there 
is a 1.5, 3.4, and 3.7 fold difference between surface modified and unmodified 80x320 nm, 
1.5 µm donut, and 6 µm donut particles, respectively, indicating that PEGylation of particles 
can significantly reduce uptake by macrophages in the lung of both nanoparticles and 
microparticles, with perhaps a stronger influence on microparticles.  Interestingly, at day 
seven, the total fluorescence of the 80x320P particles remains at  similar levels to those at 
day one which suggests slower clearance of macrophages with these particles and/or 
continued uptake of free particles residing in the alveolar space.  This hypothesis is supported 
by the fact that the 80x320U particles have a 3.2 fold reduction in total fluorescence between 
days one and seven implying clearance of particle loaded macrophages from the BALF 
and/or fewer free particles for further uptake by alveolar macrophages.   
In macrophages from the lung tissue (Figure 4.6 D), the trends in percent particle 
positive cells are identical to that of the BALF macrophages. Surface modification again does 
not play a role in the number of particle positive cells one day after instillation with 80x320 
nm and 1.5 µm donut particles. However, unlike in the BALF, the 1.5 µm donut particles had 
20% less particle positive cells than the 80x320 nm particles.  This indicates a higher 
exposure of the 80x320 nm particles to lung-residing macrophages compared to the other two 
particle sizes.  Interestingly, the percentage of 80x320 nm positive cells increases from day 
one to day seven suggesting that there may be free particles residing in the alveolar space 
which are not immediately internalized by cells in the lung.  The unPEGylated 6 µm donuts 
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have over a 5-fold increase in particle positive cells versus the unPEGylated particles at both 
one and seven days post-instillation.  In both the BALF and the lung, surface modification on 
larger micron-sized (6 µm) particles has a greater effect on uptake at early time points than 
modifications on smaller (80x320 nm and 1.5 µm) particles.  
The MFI data for the lung macrophage population (Figure 4.6 E) is quite different 
from that of the BALF.  While the fluorescence intensity of the 80x320 nm particles and 1.5 
µm donuts at day one are similar in intensity to that of the BALF, the 6P and 6U particles in 
the lung tissue had a 25% and 98% reduction in MFI, respectively. This indicates that 
macrophages in the BALF are associated with a greater number of 6 µm particles compared 
to macrophages in the lung tissue, and that the unPEGylated particles are more quickly 
cleared from the lung.  In furthering the evidence of 80x320P particles having the ability to 
be retained in the lung both free and in macrophages, the MFI value of these particles 
increases 2-fold from day one to day seven.  One would expect that if only the macrophage 
clearance rate was reduced, that the MFI levels would have a slower rate of decay, but would 
not increase over time.  Because the percent particle positive cells and the MFI increase over 
time this indicates that additional particles may be continually taken up by macrophages in 
the lung, and are retained within the lung tissue, rather than being cleared to the BALF.  At 
twenty-eight days post-instillation, all particle MFIs are significantly reduced and no 
difference is seen between particle types.      
While the total fluorescence data from macrophages in the BALF indicated a 
preference for unPEGylated particles at one day post-dose, the total fluorescence data from 
macrophages in the lung (Figure 4.6 F) shows no effect of surface modification on the total 
volume of particles internalized.  For the longer seven and twenty-eight day time points, the 
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trends hold from the MFI data, indicating an increase in particle uptake of 80x320 P particles 
from day one to day seven and then a clearance of particle-loaded macrophages by day 
twenty-eight.   
Unlike the macrophages in both the BALF and the lung, DC’s in the lung showed a 
preference for unPEGylated particles one day post-dose (Figure 4.6 G). Particle uptake of 
unPEGylated particles increased by 2.0, 4.2, and 1.6-fold in 80x320 nm, 1.5 µm, and 6 µm 
particles, respectively compared to their PEGylated counterparts.  At days seven and twenty-
eight, surface modification effects are no longer seen.   Interestingly, although there was a 
higher percentage of particle positive cells with the 80x320 U particles, the MFI data 
indicates that DCs in the lung have a much higher preference for 1.5 µm donuts, and in 
particular, the unPEGylated 1.5 µm donuts (Figure 4.6 H). One caveat for the MFI analysis 
is demonstrated with the 6 µm donut particles at days seven and twenty-eight.  Because MFI 
analyzes the median fluorescence intensity of only particle positive cells, and because of the 
extremely low percentage of particle positive DCs containing 6 µm donuts (all less than 
0.2%), the MFI may not be truly representative of the population and inferences of the data 
may not be relevant.  The vertical axis of the total fluorescence graph of lung DCs (Figure 
4.6 I) is an order of magnitude lower than that of the BALF and lung macrophages, but it 
follows the trend of the MFI data, indicating a strong preference for unPEGylated 1.5 µm 
particles at one day post-dose.  At day seven, the total fluorescence equalizes among the 
80x320 nm and 1.5 µm particles which suggests that there may be a homeostatic effect in 
regulating the volume of particles within DCs in the lung. 
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These results indicate that there are significant differences in particle uptake and 
clearance among difference resident lung cell populations.  In addition, surface modification, 
and in this case, PEGylation, of both nano- and micron-sized particles affects particle uptake 
and retention in the lung.  PEGylated 80x320 nm particle association with BALF and lung 
macrophages is seen out to twenty-eight days, suggesting a slower clearance rate of these 
cells and/or continued uptake of free particles in the alveolar region.     
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Figure 4.6  Flow cytometry analysis of particle uptake, median fluorescence intensity of 
particle positive cells, and total fluorescence. 
BALF macrophage (A-C), lung macrophage (D-F), and lung DCs (G-I) at 1, 7 and 28 days 
post-instillation. (* p < 0.05,   ** p < 0.001,  *** p < 0.0001) 
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4.4.5 Particle Distribution in the Lung Tissue 
To observe the distribution of the particles within the lung tissue, sections of frozen 
lung tissue were stained for actin, cell nuclei, and CD11c followed by analysis via 
fluorescent microscopy (Figure 4.7).  As expected, more 80x320 nm particles were observed 
in the lung tissue due to the number dosed as compared to the micron-sized particles.  
Interestingly, the PEGylated 80x320nm particles were shown to have a more homogeneous 
deposition throughout the lung tissue. Because of this higher distribution in the lung 
epithelium, the retention time of these particles may be extended, supporting the flow 
cytometry data which shows that PEGylated 80x320 nm particles can remain in the lung out 
to twenty-eight days.  The unPEGylated 80x320 nm particles were shown to be less evenly 
distributed in the lung and were often seen in larger aggregates than the unPEGylated 
particles.  More free PEGylated 1.5 µm particles were also observed compared to their 
unPEGylated counterparts.  There were no differences in particle distribution in the lung with 
the 6 µm particles.   
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Figure 4.7 Particle distribution in the lung 1 day post-instillation. 
Particles (red), Actin (gray), Nuclei (blue), CD11c (green). 
 
4.5 Discussion 
The ease of access, large absorptive surface area, and reduced enzymatic activity of 
the lung make it an attractive target for both local and systemic drug delivery, yet drug 
particles must circumvent the lung’s highly efficient particle clearance mechanisms in order 
to successfully deliver their payload. In addition, the drug delivery vehicles must be inert, 
preferably not contributing to an adverse inflammatory response.  While there are a multitude 
of studies in environmental toxicology analyzing the retention and inflammatory effects of 
polystyrene, pollutant and industrial (diesel exhaust, dust, carbon fiber) particle burdens in 
the lung, there are few studying the effect of polymeric drug carriers. In this study, we 
wanted to observe the effects of size and surface modification on polymeric particles on 
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particle retention and potential inflammatory consequences in the lung.  The findings from 
these studies may help articulate important particle parameters towards designing more 
efficient pulmonary drug delivery vehicles.  Here, we utilize PRINT technology to fabricate 
monodisperse, cross-linked hydrogel particles of nanometer and micrometer sizes that were 
further modified by adding an additional PEG layer to the particle surface.   
For therapeutic applications targeting sentinel dendritic cells, our findings show that 
lung DCs have a significant preference for unPEGylated 1.5 µm particles.  Although there 
are a higher percentage of particle positive DCs in the lung with the 80x320U particles, the 
total volume of internalized particles is over 3-fold greater for the 1.5U particles.  From a 
more physiological view, we show that the DC population that migrates out to the airway 
surface can potentially be modulated by the surface modification of the particle; 
unPEGylated 80x320 nm and 1.5 µm particles were shown to double the DC population in 
the BALF one day post-dose. 
Interestingly, although the in vitro macrophage uptake studies showed that PEGylated 
particles of all three particle sizes tested had a significant decrease in number of cells with 
particle positive cells compared to their unPEGylated counterparts, only the 6 µm donut 
particles followed this trend in BALF and lung macrophages with a 2-fold and 5-fold 
decrease in particle positive cells, respectively.  This indicates that PEGylated 6 µm donuts 
may be promising drug carriers as well for disease targets where de-targeting macrophage 
uptake is preferred.  Taking into account total fluorescence, or overall amount of particles 
internalized, there was indeed a difference due to surface modification of all particle sizes in 
the BALF indicating the ability to reduce mass of particles taken up by immune cells in the 
lung via surface PEGylation.   
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Our results show that these particles can reside in the lung out to twenty-eight days 
without causing an inflammatory response.  In particular, the 80x320 nm and 1.5 µm 
particles are seen in BALF and lung cells out to a month which may make them a prime 
candidate for sustained release of drug for diseases targeting macrophages in the lung, such 
as tuberculosis.  Additionally, the PEGylated 80x320 nm actually show an increase in uptake 
from day one to day seven, indicating that there are likely free particles residing in the 
alveolar airspace and/or epithelial tissue.  This is supported by fluorescent microscopy of the 
lung tissue which shows the particles significantly distributed throughout the epithelial cells 
of the lung.  Thus, this may also make these particles ideal for gene delivery to treat cystic 
fibrosis and local delivery of therapeutics to airway cells to treat chronic obstructive 
pulmonary disease (COPD).   
 
4.6 Conclusions 
This study on PRINT particle distribution and retention in the lung indicates this 
platform as a promising and flexible system for testing and developing sustained drug release 
systems in the lung.  Not only are these particles non-inflammatory, but they can also be 
retained in the lung for at least a month, with potential to serve as drug depots.  Surface 
modification of these particles can also significantly affect uptake by certain cell populations 
in the lung, thus allowing for cell-specific targeted delivery of therapeutics.  We hope that by 
applying the knowledge from these fundamental biological studies of particle interactions in 
the lung to pulmonary delivery applications we can design more efficient drug carriers. 
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4.7 Supplemental 
Particle shape has been shown to induce different cytokine responses in several 
different studies.  Hutter et al. demonstrated that sphere, rod, and “urchin”-shaped gold 
nanoparticles dosed to microglial cells would release different levels of cytokines [72].  
Other studies have shown a size-influenced cytokine release where 0.49, 4.3, and 7.2 µm 
polyethylene particles were demonstrated to increase production of IL-6, IL-1β, and TNF-α 
[164].  Elongated ultra-high molecular weight polyethylene (UHMWPE) particles were 
documented to cause more severe local inflammatory responses than globular particles [165].  
The studies involving polyethylene particles are often in response to particulate wear debris 
from implanted prosthetics.  For lung relevance, elongated particles of mica and asbestos 
were shown to be more potent stimulators of cytokines [166, 167].  However, there are no 
published studies investigating shape effects on in vivo cytokine responses of polymer-based 
micron-sized particles in the lung.   
In this study, PRINT fabrication was used to generate PEG particles of different 
shapes, sizes, and surface chemistries (lollipops, 80x320 nm, 1.5 µm donuts, and 6 µm 
donuts; all sizes have groups that are PEGylated (P) and unPEGylated (U)).  Due to the 
micro-molding technique utilized by PRINT, a monodisperse population of particles was able 
to be generated (Figure 1).  PEGylated and unPEGylated lollipop shaped particles were 
instilled into the lungs of mice using the same particle composition and protocol as described 
in Chapter 4.  BALF supernatant was collected for cytokine analysis and lungs were also 
frozen and stained for histology.  A shape-based effect on cytokine release was seen in the 
BALF where only the lollipop-shaped particles were seen to induce cytokine production.   
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Figure 4.8 Lollipop-shaped particles generated with PRINT 
 
An 8-plex mouse cytokine array (Invivogen) was used to assess the immune profile of 
the BALF after particle dosing.  IL-6, IL-1β, TNF-α, CCL2, CCL3, CCL4, CCL5, and 
CXCL2 cytokines were measured in the BALF.  A summary of the function of each cytokine 
is listed in the Table 4.2.  Cytokine concentrations of instilled particles at 24 hours post-dose 
are shown in Figure 2.  Surprisingly, only the lollipop particles induced any significant 
cytokine response.  More interestingly, there was observed to be a surface-modification 
response to the induction of CCL2 where the unPEGylated particles resulted in over a 4-fold 
increase in CCL2 concentration compared to PEGylated lollipop particles.   
Table 4.2 Summary of Cytokine Functions 
Name Induced by Cell Source Cell Target 
IL-6 
Infection, tissue damage 
Macrophages, monocytes, B 
cells, DCs 
B cells, T helper cells, NK 
cells, Epithelial cells 
IL-1β 
 
Infection, tissue damage Macrophages Lymphocytes 
TNF-α 
 
Infection, gram-neg 
bacteria 
Macrophages, T-cells Neutrophils, Macrophages 
CCL2 (MCP-1) 
Infection, tissue damage 
Macrophages, monocytes, 
DCs 
Monocytes, memory T 
cells, DCs 
CCL3 (MIP-1α) 
 
Bacterial endotoxins Macrophages Leukocytes 
CCL4 (MIP-1β) 
 
Bacterial endotoxins Macrophages Leukocytes 
CCL5 (RANTES) Viral infection of epithelial 
cells 
T cells, Lymphocytes, 
Epithelial cells 
T cells, Monocytes, 
Eosinophils 
CXCL2 (MIP-2) 
 
Infection, inflammation Macrophages, monocytes Leukocytes 
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It has been shown previously that PEG-coated gold nanorods have decreased IL-6 and 
TNF-α release compared to particles coated with poly(sodium 4-styrenesulfonate) (PSS), a 
negatively charged polyelectrolyte, or coated with poly (diallyldimethylammonium chloride) 
(PDAC), a positively charged polyelectrolyte [168].  This decreased cytokine production 
may be due to fewer PEGylated particles internalized by cells in the BALF, however, both 
PEGylated and unPEGylated lollipop particles generated high concentrations of CCL4 which 
is a primary recruiter of leukocytes.  This data may demonstrate that certain particle 
parameters may have a greater influence in the release of specific cytokines. 
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Figure 4.9 Cytokine concentrations 24 hours after particle instillation in the BALF  
The top figure includes the cytokine analysis of all particles tested.  The bottom figure 
displays only the cytokine concentrations of the saline and LPS controls and the lollipop 
particles. ( ** p < 0.001 ) 
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The increased release of cytokines was also verified by flow cytometry which showed 
enhanced neutrophil recruitment into the BALF (Figure 3).  Neutrophils were gated based on 
Ly6G expression in the flow cytometry analysis and the population in the LPS positive 
control is circled in red.  This neutrophil population is also seen in the lollipop-treated mice, 
but not in the mice instilled with 80x320 nm or 6 µm donut particles. 
 
Figure 4.10 Flow cytometry analysis of neutrophil population in the BALF 
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Fluorescent confocal microscopy of lung tissue additionally validated these 
observations.  Areas of increased cell infiltration are seen in the particles dosed with 
unPEGylated lollipops 24 hours post dose (Figure 4).   
 
Figure 4.11 Fluorescent microscopy of lung tissue. 
Cell nuclei (blue), Particles (red), Actin (Gray). 
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Previous litereature has shown increased cytokine production after intratracheal 
instillation of crocidolite asbestos and refractory ceramic fibres 2-10 µm in length [169, 170].  
Studies on the effect of fiber length on lung pathogenicity demonstrated that longer amosite 
asbestos induced inflammation while shorter amosite fibers presented virtually no 
inflammation [171, 172].  The majority of research investigating particle length and lung 
inflammation has focused on exposure of mineral-based asbestos found in industrial settings.  
Milling is often used to shorten long fibers for these studies and often results in a 
significantly heterogeneous population of fiber lengths.   
In this work, polymer-based, monodisperse particles were utilized to assay the effect 
of particle geometry on lung inflammation.  Polymer-based drug carriers are actively being 
explored for therapeutic applications, but their inflammatory potential in the lung has not yet 
been fully realized.  Using PRINT technology, monodisperse particle populations can be 
generated to eliminate the added variability of differing particle sizes thus allowing one to 
better attribute geometry-based effects of specific particle dimensions.  While PRINT PEG 
particles of rod shape (80x320 nm) and donut shapes (1.5 µm and 6 µm) have previously 
been shown to be non-inflammatory when dosed in the lung [143], the cytokine release 
profiles of the lollipop-shaped particles indicate that there is a shape-based response.  In 
addition, PEGylation of these lollipop particles was also shown to affect the magnitude of 
cytokine release, indicating a surface-modification response.  While many applications of 
drug delivery to the lung will prefer inert carriers, therapies targeting the manipulation of the 
immune system may benefit from further understanding of particle characteristics which can 
influence the immune response.  The lung has also been shown to be a “hub” for the 
programming of immune cells directing them to different areas of the body [151].  Thus, 
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these studies have shown the ability to shape the immune response in the lung based on 
changing specific particle parameters.  Future studies may further demonstrate the ability to 
precisely tune the immune response based on programmable particle features.  
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CHAPTER 5 
 
SUMMARY AND FUTURE DIRECTIONS 
 
5.1  Summary 
The overall scope of this work was to utilize the PRINT fabrication process to 
generate a set of particles with precisely tuned particle parameters such that the influence of 
these individual parameters on biological systems could be systematically investigated.  The 
lung was chosen as the primary target of interest due to its clinical relevance and the need to 
develop drug carriers that can overcome its highly efficient clearance mechanisms. The quick 
immune response to foreign invaders and its influence of the body’s adaptive immunity also 
made the lung an interesting system to explore potential immunomodulatory effects of 
different particle parameters.   
Taking advantage of PRINT technology’s ability to generate particles of non-
spherical geometries, several unique micron-sized polymer-based shapes were designed and 
fabricated.  These shapes had physical geometries varying from 1 µm to 11 µm in diameter 
and volumes ranging from 1 µm
3
 to 40 µm
3
.  Yet, all these shapes had aerodynamic 
diameters between 1 µm and 5 µm, making them ideal for deep lung deposition.  When 
dosed in vitro to alveolar macrophages, a significant difference in uptake was seen among 
particle shapes with cells less likely to internalize shapes with larger volumes.  The ability to 
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tailor macrophage uptake offers the opportunity to develop cell-specific drug carriers.  
Therapies that would benefit from increased macrophage internalization of antibiotic drugs 
such as tuberculosis could be dosed with a particle shape more likely to be internalized.  For 
drugs that would need to avoid rapid macrophage sequestration or clearance from the lung, 
shapes that can de-target macrophages such as the 6 µm donuts would be ideal.   
In addition, it was also observed that macrophages had a preference for initiating 
phagocytosis at the more narrow ends of the particle shapes tested.  This was demonstrated 
with the lollipop shaped particles in which over 70% of particles still undergoing 
phagocytosis were internalized with the “stick” end first.  This result corresponds to other 
work which has described the ability of macrophages to recognize shape and may point to an 
evolutionary process of awareness from the body’s constant exposure to bacteria, many of 
which are rod-shaped. 
To lend more clinical and field relevance to these initial studies, collaboration with an 
immunology laboratory was initiated to observe the residence time of these particles in the 
lung and to explore the influence particles may have on the innate and adaptive immune 
system.  The goal of this study was to investigate which particle parameters may trigger 
inflammation in the lung and which parameters may render a particle more immunologically 
inert.  These particles were composed of the FDA approved polymer, PLGA, or a 
biocompatible polymer, PEG, and ranged in size from 80x320 nm to 6 µm in diameter.  In 
vitro testing of these particles with murine bone marrow-derived macrophages showed that 
both PLGA and PEG particles of all sizes did not induce inflammatory cytokine release.  
Instillation of these particles into the lungs of mice was conducted to observe the potential 
inflammatory effects of these particles in a more complex biological system and to explore 
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the effect of size and shape on in vivo particle uptake.  In correlation with the in vitro results, 
both PLGA and PEG particles of all sizes did not induce cytokine release as measured in the 
BALF and serum.  As expected, smaller particles were taken up more significantly by cells in 
the BALF, but all particle sizes were still seen out to seven days in the lung.  It was also 
observed that the 6 µm PEG particles could remain in the lung tissue for two weeks without 
causing overt signs of inflammation.  This work has shown that PRINT PLGA and PEG 
particles have a good safety profile conducive towards their use as drug delivery vehicles in 
the lung.  Thus, future applications can utilize these immunologically inert particles for 
sustained drug delivery in the lung.   
A more comprehensive study on the cellular fate and inflammatory response of nano- 
and micro-particles in the lung was undertaken to further investigate the use of PRINT 
particles as potential pulmonary drug delivery vehicles.  In addition to particle size and 
shape, particle surface chemistry was explored to analyze the effects PEGylation may have 
on particle residence time and macrophage uptake in vivo.  Again, PEG particles of 80x320 
nm, 1.5 µm and 6 µm diameters were fabricated and an additional PEG5k was covalently 
attached to form a stealthing layer on the surface of the particles.   
Dendritic cells were observed to have a propensity for taking up unPEGylated 1.5 µm 
donut-shaped particles which may make these particles ideal for therapies targeting DCs such 
as vaccines or immunoengineering applications.  PEGylation effects on overall percentage of 
macrophage uptake were most noticeable in the 6 µm donut-shaped particles in both the 
BALF and lung data sets in which there was a 2-5 fold decrease in particle positive cells with 
administration of PEGylated particles compared to an unPEGylated control.  However, 
taking into account total fluorescence, or overall amount of particles internalized, there was 
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indeed a difference due to surface modification of all particle sizes in the BALF indicating 
the ability to reduce mass of particles taken up by surface PEGylation.  Most interestingly, 
there was shown to be an increase in internalization of PEGylated 80x320 nm over time 
indicating that free particles are localized in the airway even out to seven days.  A significant 
number of macrophages were still particle positive with the PEGylated 80x320 nm particles 
even out to twenty-eight days after administration.  Analysis of IL-6 and MIP-2, two 
inflammatory cytokines, in the BALF indicated that there was no significant cytokine release 
from the PEGylated and unPEGylated micron-sized donut and the nanometer-sized rod-
shaped particles tested.  Thus, these tests confirm the immunologically inert characteristics of 
these particles and give rise to their potential as sustained-release drug carriers in the lung.   
Interestingly, the lollipop-shaped polymeric particles were shown to induce cytokine 
production which supports previous literature that longer fibrous particles are more likely to 
induce inflammatory responses in the lung. 
 
5.2 Future Directions 
Utilizing PRINT as a toolbox to further fundamental understanding of cellular 
processes would be an area of great interest.  Natural pathogens and particulates are 
optimized for specific functions in vivo and embody many desired traits for drug delivery 
vehicles.  Current synthetic drug carriers have not yet been able to successfully replicate the 
efficiency of these innate properties of natural particulates.  However, more advanced 
technology and creative approaches towards bio-mimetic carriers have inspired and greatly 
advanced the field of drug delivery.   
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Bacteria- and virus- based mimetics often take advantage of the particulate nature and 
size of the pathogen.  Synthetic particulate vaccines utilize the findings that antigen 
presenting cells (APCs) internalizing particle-associated proteins leads to 1,000-fold more 
efficient antigen processing and presentation to CD8+ T cells than internalization of the 
soluble form of the protein [173, 174].  The co-presentation and delivery of particulate-
associated danger signals and antigens to APCs have been shown to trigger the host response 
[175, 176].  Viruses smaller than 100 nm in size have been shown to more efficiently traffic 
to lymph nodes and promote increased immune responses and many synthetic polymeric 
antigen-carrying particles have exploited this feature to increase vaccine efficiency  [177, 
178].  Others have mimicked the surface properties of viruses which allow for increased 
diffusion of the particle through mucus for better intracellular delivery of cargo [54].   
PRINT particles mimicking these natural characteristics of size and activation of antigen 
presentation have been explored and yielded promising results towards more efficient 
vaccines.   
Along these lines, the work in Chapter 4 of this thesis has shown preferential uptake 
of unPEGylated 80x320 nm and 1.5 µm particles by dendritic cells in the lung.  As these 
particles have also been shown to be immunologically inert, unintended inflammatory 
responses in vivo upon particle dose are avoided.  When dosed at equal mass (50 µg) into the 
lung, 80x320 U particles resulted in a greater number of particle-associated dendritic cells 
while the 1.5 U particles resulted in a greater MFI in DCs indicating that a greater mass of 
1.5 U particles are taken up by DCs.  It would be interesting to add a surface-conjugated 
antigen and examine the immune response of antigen processing by number of cells with 
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associated antigen or by mass of the antigen internalized.  This study could tease out particle 
parameters that may be more ideal for vaccine applications. 
The PEGylated 80x320 nm particles in the same study were observed to reside in 
close to half of total lung macrophages even twenty-eight days after instillation.  This lends 
itself to potential applications for the treatment of tuberculosis.  Nebulized poly(DL-lactide-
co-glycolide) particles (186-290 nm in size) loaded with antitubercular drugs have 
demonstrated therapeutic concentrations in the lung of guinea pigs out to eleven days and no 
tubercle bacilli were detected after five doses while oral doses taken daily for forty-six days 
were required for the same therapeutic benefit [179].  This demonstrates the utility of a 
sustained-release platform that can reduce the dosing regime and potentially increase patient 
compliance for the treatment of TB.  Loading these PRINT particles with anti-TB drugs such 
as isoniazid, rifampin, pyrazinamide or a combination of first-line treatments and triggering 
release by pH-sensitive cross-linkers or particle swelling would allow for the targeted 
delivery of these drugs to bacteria-harboring macrophages in the lung.  Current TB 
treatments utilize oral drugs with undesirable side effects, thus, a localized treatment directly 
to the lung would be ideal for increasing the therapeutic dose at the site of action as well as 
reducing systemic toxicities.  With the potential to sustain therapeutic concentrations for out 
to a month or longer would greatly reduce number of doses required and simplify the dosing 
schedule for TB patients.  While 80x320 nm sized particles may not be efficiently deposited 
in the alveolar region, incorporation of these nano-sized particles into larger micron-sized 
carriers is a possibility.  Future work building off of these results may incorporate the use of 
mothership particles in which the 80x320 nm particles are embedded in a larger, more 
aerodynamically ideal particle for targeted lung delivery (Figure 5.1). 
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Figure 5.1 Mothership Particles. A) Bright field image of a 6 µm PLGA particle with 
80x320 nm PEG particles embedded within. B) Fluorescence image of the same particle in 
which the 80x320 nm particles have an incorporated fluorescein dye (green).   
 
Physical characteristics of bacteria have also been shown to affect macrophage 
responses.  Lactobacillus bacteria strains with rigid cell walls resistant to intracellular 
digestion were observed to induce macrophage production of IL-12 [180].  Increased 
substrate rigidity has been demonstrated to affect innate functions of macrophages such as 
the uptake of particles [124, 181].  More rigid nanoparticles were also shown to be more 
significantly phagocytosed by RAW 264.7 murine macrophage cells [182].  The 
aforementioned studies were performed in vitro with cultured cell lines.  With the in vivo 
instillation and particle uptake analysis protocols optimized from past experimental studies in 
the DeSimone group, it would be interesting to explore the in vivo response of lung cells to a 
series of particles that ranged from low to high modulus.  The ability of PRINT to generate 
particles of the same geometry but with different modulus has been shown previously with 
red blood cell mimics [99, 100].  Can we further de-target macrophages with highly 
swellable and/or less rigid particles?  In addition to investigating the effect of particle 
modulus on particle uptake, looking into the effects of lung disease states on macrophage 
uptake would also be interesting.  Pneumonia is often associated with significant increases in 
lung tissue rigidity [183, 184].  Bacterial pathogen associated molecular patterns (PAMPs) 
and cytokines have also been shown to influence tissue rigidity [185, 186].  Does the disease 
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state affect the modulus range at which macrophages will more significantly take up 
particles? Because pneumonia is a bacteria-based disease, will macrophages be more 
activated to ingest particles of a greater modulus range to ensure containment of the 
pathogen?  These studies will not only enhance our understanding of influencing 
characteristics on innate macrophage functions, but will also allow us to tailor more optimal 
design parameters of drug delivery carriers for specific diseases of the lung. 
Environmental toxicologists have extensively explored the role of environmental 
particulate burdens in the lung and their effects on lung injury.  Studies on particles of TiO2 
have shown that ultrafine particles (< 50 nm) elicit a greater inflammatory response in the 
lung compared to larger particles due to increased particle localization in the interstitium and 
greater surface area interactions with macrophages [187].  Overloading of the rat alveolar 
macrophages with dust particles on the order of 60 µm
3
/AM initiated reduction of particle 
clearance from the deep lung [188, 189].   Overloaded macrophages displayed impairment in 
chemotactic responses (cell motility) and particle clearance functions [190, 191].  Few 
studies have investigated the effect of repeated dosing of polymeric drug carriers.  As 
emerging matrices for inhaled drug delivery, there is a need to assess their toxcicological 
effects in the lung.  Although the fabricated hydrogel PRINT particles (80x320 nm, 1.5 µm 
donuts, and 6 µm donuts) have been shown to be inert upon installation in the lung, issues 
such as impairment of lung clearance or alveolar macrophage uptake of pathogens post 
particle dose remain to be explored.  Proposed experiments to investigate these responses 
would be to analyze particle uptake and cytokine responses in mice instilled with multiple 
doses of polymeric particles with similar protocols described in Chapter 4.  Each particle 
dose would incorporate a different colored dye, thus allowing for the analysis of particle 
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uptake based on dose number.  In addition, a bacterial challenge can be included to measure 
pathogen clearance effects of particle loaded macrophages.  These studies would help guide 
dosing regimens of these polymeric drug carriers to enhance therapeutic efficacy without 
compromising the innate immune response.       
Additional studies comparing the cytokine properties of particles dosed through the 
pulmonary route verses other routes of administration would perhaps provide insights on the 
influences of the biological environment on the cytokine response. This information would 
be particularly important for inhaled drug particles that may enter the systemic circulation.  A 
biodistribution study of inhaled PRINT particles and their drug cargo would also be 
interesting to analyze local verse systemic delivery of particles and drugs.   
Generating a more systematic series of shapes to explore the kinetics of macrophage 
phagocytosis and the resulting physiological response would enhance our knowledge on the 
influence of particle geometry.  Experiments in this thesis used shapes that had distinct 
geometries, but no unifying control parameter (aside from the different diameter donut 
shapes).  Fabricating particles with differing geometric shapes, but with the same volume 
would allow for a more controlled comparison of particle geometry.  In particular, it would 
be interesting to look at the “ball-and-stick” family of shapes to investigate how particle 
angles or number of arms may affect macrophage particle uptake and cytokine response.  
Can we further de-target macrophages purely based on geometry?  Are there certain 
geometries that induce frustrated phagocytosis or increased cytokine release?  From Section 
4.7, it was shown that lollipop particles induced the release of cytokines in the BALF 
significantly more than other particle shapes.  Expounding on the research from Chapter 2, 
what are the cellular mechanisms underlying this phenomenon of shape-induced cytokine 
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release?  Is it a frustrated phagocytosis effect?  Does orientation of particle internalization 
affect these macrophages?         
In summary, this work has demonstrated the modularity of the PRINT process to 
fabricate particles with specifically tuned parameters.  Because of this, individual particle 
characteristics such as size, shape, and surface chemistry could be systematically tested in 
complex biological systems.  Thus, optimal particle parameters for specific therapeutic 
applications can be applied for more efficient disease treatments.  The findings from this 
research can be used in the development of sustained-release drug delivery in the lung, 
specific cell-based therapies, and immunomodulatory applications.   
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